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GENERAL ABSTRACT 
 
 Background: Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group 
of conditions that share chronic arthritis as a common characteristic. Current classification 
criteria for chronic childhood arthritis have limitations. Despite new treatment strategies 
and medications, some continue to have persistently active and disabling disease as adults. 
Few predictors of poor outcomes have been identified.  
 Objectives: This thesis comprises two complementary studies. The objective of 
the first study was to identify discrete clusters comprising clinical features and 
inflammatory biomarkers in children with JIA and to compare them with the current JIA 
categories that have been proposed by the International League of Associations for 
Rheumatology. The second study aimed to identify predictors of short-term arthritis 
activity based on clinical and biomarker profiles in JIA patients.  
Methods: For both studies we utilized data that were collected in a Canadian 
nation-wide, prospective, longitudinal cohort study titled Biologically-Based Outcome 
Predictors in JIA. Clustering and classification algorithms were applied to the data to 
accomplish both study objectives. 
 Results: This research identified three clusters of patients in visit 1 (enrolment) 
and five clusters in visit 2 (6-month). Clusters revealed in this analysis exposed different 
and more homogenous subgroups compared to the seven conventional JIA categories. In 
the second study, the presence or absence of active joints, physician global assessments, 
and Wallace criteria were chosen as outcome variables 18 months post-enrolment. 
Among 112 variables, 17 were selected as the best predictors of 18-month outcomes. The 
panel predicted presence or absence of active arthritis, physician global assessment, and 
Wallace criteria of inactive disease 18 months after diagnosis with 79%, 82%, and 71% 
accuracy and 0.83, 0.86, 0.82 area under the curve (AUC), respectively. The accuracy 
and AUC values were higher compared to when only clinical features were used for 
prediction.  
Conclusion: Results of this study suggest that certain groups of patients within different 
JIA categories are more aligned pathobiologically than their separate clinical 
categorizations suggest. Further, the research found a small number of clinical and 
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inflammatory variables at diagnosis can more accurately predict short-term arthritis 
activity in JIA than clinical characteristics only.   
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DESCRIPTION OF CHAPTERS 
Chapter 1- Overview and rational for the research 
The first chapter is a brief overview of backgrounds, rationales, and objectives of 
studies included in this thesis. 
Chapter 2- Background literature review 
1- The background literature review provides an overview of previous 
classifications of childhood arthritis. 
2-  A review of biomarkers associated with JIA is provided. The most important 
inflammatory biomarkers involved in the pathophysiology of JIA are 
explained in this chapter.  
3- Gene and human leukocyte antigen (HLA) characteristics in JIA are discussed 
briefly. 
4- A review of suggested JIA outcome measures and predictors of disease 
activity is provided. 
5- Analytic methods, including specific variable selections, clustering and 
classification algorithms are explained.  
Chapter 3- Study 1 manuscript  
Chapter 4- Study 2 manuscript 
Chapters 3 and 4 are manuscripts of studies 1 and 2, respectively. Each 
manuscript includes the introduction, methodology, results, discussion and conclusion 
generated from the study. 
Chapter 5- Overall discussion and conclusion  
The Discussion and Conclusion chapter provides general, integrated commentary 
relating to both studies.  
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CHAPTER 1  
OVERVIEW AND RATIONAL FOR THE RESEARCH 
1.1 Background 
Chronic childhood arthritis is a heterogeneous group of diseases categorized 
predominantly by clinical manifestations (1). A classification proposed in 2001 by a 
subcommittee of the International League of Association for Rheumatology (ILAR) 
denotes the most current system for classifying chronic childhood arthritis (Table 1.1) 
(2). The impetus for developing the JIA classification system was a desire to establish 
internationally standardized disease categories to facilitate communication and research 
collaborations (3). 
 Classification criteria for chronic childhood arthritis that preceded the ILAR JIA 
criteria were the American College of Rheumatology (ACR) criteria for Juvenile 
Rheumatoid Arthritis (JRA) proposed in 1970 (4), and the European League Against 
Rheumatism (EULAR) criteria for Juvenile Chronic Arthritis (JCA), proposed in 1977 
(5). 
Both the ACR and EULAR classification systems are based on clinical features at 
disease onset. As with earlier iterations of childhood arthritis classifications, the utility of 
the current JIA classification system is limited as it was not devised primarily to predict 
clinical courses, reliably guide treatment choices, or predict treatment responses. Also, re-
classification of a patient might be necessary if clinical manifestations, test results, or 
pertinent family medical history information change. While JIA categories are intended 
to be mutually exclusive, some overlaps exist despite the application of exclusion criteria 
that aim to preserve category purity. In addition, the exclusion criteria can lead to 
ambiguity and inaccuracies in classifying some patients. 
 Only two biomarkers, rheumatoid factor (RF) and HLA-B27, are considered in 
JIA classification (2). The principle premise underlying the research described herein is 
that a more comprehensive array of biomarkers that could eventually include genomic, 
proteomic, transcriptomic, immunomic and metabolomic features, when combined with 
clinical characteristics could yield a more refined, biologically-based classification 
system. It also can provide insight into chronic childhood arthritis pathogenesis, and aid 
in predicting disease course and outcomes. 
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Although not considered in current chronic childhood arthritis classification 
systems, genomic profiles tend to be distinguishable among JIA categories. 
 
Table 1.1 ILAR JIA classification (2).   
 
   a. Psoriasis or a history of psoriasis in the patient or first-degree relative. 
        b. Arthritis in an HLA-B27 positive male beginning after the 6th birthday. 
c. Ankylosing spondylitis, enthesitis related arthritis, sacroiliitis with inflammatory 
bowel disease, Reiter’s syndrome, or acute anterior uveitis, or a history of one of these      
disorders in a first-degree relative.  
d. The presence of IgM rheumatoid factor on at least 2 occasions at least 3 months apart.  
e. The presence of systemic JIA in the patient.  
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As examples, certain HLA allotypes and nucleotide polymorphisms confer JIA 
susceptibility while others appear to be protective (6). Certain single nucleotide 
polymorphisms (SNP1s) are associated with JIA categories (7, 8).  
There has been increasing interest in identifying molecules involved in regulating 
immune responses that relate to susceptibility to, and outcome of JIA. Proteomic data have 
been studied in different subtypes of JIA with significant associations identified (9-15). The 
inflammatory process is mediated by an array of innate regulators including interleukins, 
chemokines, growth factors, and matrix metalloproteinases (MMPs). In the context of 
JIA, some of these biological markers, such as IL-6 and IL-1 in systemic JIA (16, 17) 
reflect inflammatory activity while others, like MMPs, receptor activator of nuclear factor 
kappa-B ligand (RANKL), and Osteoprotegerin (OPG) are predictive of disease 
outcomes (18, 19). Distinctive cytokine profiles and acute phase protein responses in 
polyarticular and systemic JIA have been identified (6, 20). This accumulating evidence 
of biomarker associations with JIA subgroups supports a need to more thoroughly study 
JIA in the context of clinical and biomarker profiles and to determine if panels of 
attributes can more precisely distinguish subsets of children with chronic arthritis and 
predict their disease outcomes. 
 In addition to considering the importance of clinical and biomarker features for 
classification of chronic childhood arthritis, we aimed to determine the utility of baseline 
clinical-biomarker panels for predicting short-term disease course and outcomes. Being 
able to effectively predict the disease trajectory and eventual outcomes would help 
inform the timing and aggressiveness of treatment interventions. 
Identification of the time frame during which the correct therapeutic choice can 
change the pathophysiology of disease and improve outcomes is important for optimizing 
care (21). In JIA early initiation of aggressive treatment, especially in systemic arthritis 
and polyarticular arthritis categories, results in better outcomes (22). In contrast, patients 
with mild disease do not require aggressive, potentially harmful, and expensive 
treatments as more moderate therapies are efficacious. While timing and aggressiveness 
                                               
1 SNPs are variations in DNA sequence that occur by changing a single nucleotide 
in the genome. Each individual has many SNPs, which constitutes a unique DNA pattern 
for that person. 
 
 
   
 
5 
of treatment interventions in JIA are currently guided by clinical characteristics 
predominantly, it is conceivable that incorporating biomarker profiling in the therapeutic 
decision-making process could further enhance treatment effectiveness, minimize adverse 
effects of therapy and reduce cost. 
 Different descriptors of JIA states of disease activity have been proposed 
including, as examples: mild, moderate, or severe disease; inactive disease; minimal 
disease activity; and remission on/off medication (23-27). ACR criteria defined disease as 
active/inactive (in remission) in oligoarticular, polyarticular, and systemic JRA by using 
the number of joints with active arthritis, physician global assessment (PGA), clinical 
manifestation of systemic arthritis, presence of active uveitis, erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP) levels, and duration of morning stiffness (26). A 
composite disease activity scoring system, the juvenile arthritis disease activity score 
(JADAS), has been developed for assessment of disease status. JADAS includes four 
variables: number of involved joints, PGA, parent/child ratings of well-being, and ESR or 
CRP (25, 27). The state of minimal disease activity has been described using number of 
active joints, PGA, and a parent’s global rating of well-being in polyarthritis and 
oligoarthritis (28). A joint was defined as active in accordance with the definition 
prescribed in the ILAR JIA classification. Specifically, “[active] arthritis is swelling 
within a joint, or limitation in the range of joint movement with joint pain or tenderness, 
which persists for at least 6 weeks, is observed by a physician, and is not due to primarily 
mechanical disorders or to other identifiable causes” (2). In accordance with this 
definition, an active joint may be effused or not but an effused joint is always active. 
 Wallace et al. proposed a set of criteria for inactive JIA including: no joints with active 
arthritis, no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy 
attributable to JIA, no active uveitis, normal ESR or CRP, PGA that indicates no disease 
activity (29).  
 Clinical and laboratory features have been used to determine disease course and 
outcome (23, 30). Disease activity states, joint damage, functional ability, and quality of 
life are characteristics typically applied to determine disease outcome (31-37). Number of 
active joints at onset, polyarticular onset of JIA, Child Health Assessment Questionnaire 
(CHAQ) responses, PGA, parent’s global assessment, and joint symmetry were 
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determined to have predictive utility. There is a paucity of information on the use of 
genetic and immunological characteristics as predictors of JIA outcomes (20, 32, 38). 
1.2 Purpose of the study 
The purposes of this thesis are: 1) to identify discriminating clusters of clinical 
and biomarker characteristics and determine how well such clusters align with current 
JIA categories; and 2) to identify early predictors of JIA outcome based on clinical 
manifestations and biomarker profile of the patients at first presentation in a JIA 
inception cohort. 
The results could either support the appropriateness of the current JIA categories 
and predictors or possibly indicate that inflammatory biomarkers might add precision to 
categorizing and outcome prediction of chronic childhood arthritis.  
1.3 Software used for analyses  
To realize these aims, clinical and biological data previously collected in a 
national study, the Canadian Biologically-Based Outcome Predictors (BBOP) in JIA 
study, were used (39). Data mining algorithms were applied for data analyses. Data were 
pre-processed to make them suitable for input into data mining algorithms. Raw data are 
highly susceptible to missing values, outliers, noisy data, and inconsistency.  
Pre-processing data is an important step to enhance data efficiency. Pre-processing 
includes several techniques such as cleaning, integration, transformation, and reduction 
(40). SPSS software (IBM®) was used for pre-processing and data ranking techniques. 
Several R software packages were used for principal component analysis (PCA) and 
clustering (study 1), and the software package Waikato Environment for Knowledge 
Analysis (Weka) was used for predicting JIA outcome (study 2). Weka is open source 
software with a collection of machine learning algorithms and data pre-processing tools. 
It is easy to use and a powerful data mining tool (41). 
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CHAPTER 2  
LITERATURE REVIEW 
2.1 Juvenile idiopathic arthritis definition and classification 
 Arthritis, which is inflammation within a joint, is defined as joint swelling or 
effusion, or the presence of two or more of the following: limitation of range of motion, 
tenderness or pain on motion, and increased heat in one or more joint (42). Arthritis is the 
most common chronic childhood conditions. Among the many different forms of 
childhood arthritis, JIA is the most common class. JIA is a heterogeneous group of 
chronic childhood arthritis conditions for which the cause is unknown. It is a potentially 
disabling condition with incidence rate of 7.8/100,000 and a prevalence of 32.6/100,00 in 
(43). 
 That chronic arthritis commonly afflicts children is a relatively contemporary 
realization. However, early archaeological evidence has shown evidence of arthritis in 
children dating from as early as the 10th century and there are reports of childhood 
arthritis over the ensuing centuries (44). 
 Until the late 19th century, arthritis beginning during childhood was considered to 
be the same disease as adult onset arthritis. However, in 1883 rheumatic diseases in 
children as a distinctive class of pediatric disease was highlighted at a meeting of the 
British Medical Association (45, 46). Dr. George Frederic Still, in his 1897 doctoral 
dissertation, further elucidated the characteristics of chronic arthritis in children and 
introduced the idea that childhood onset arthritis was distinguishable in many cases from 
adult onset rheumatoid arthritis (RA) (1). He described the disease based on his 
observation of 22 children with chronic arthritis and wrote:  
“The occasional occurrence in children of a disease closely resembling the 
rheumatoid arthritis of adults has been recognized for several years. The identity 
of the disease seen in children with that in adults has never, so far as I am aware, 
been called in question. Although the disease known as rheumatoid arthritis in 
adults does undoubtedly occur in children, the disease which has most commonly 
been called rheumatoid arthritis in children differs both in its clinical aspect and 
in its morbid anatomy from the rheumatoid arthritis of adults; it presents, in fact, 
such marked differences as to suggest that it has a distinct pathology. The cases 
hitherto grouped together as rheumatoid arthritis in children include, therefore, 
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more than one disease; and it will be shown that there are at least three distinct 
joint affections which have thus been included under the one head, rheumatoid 
arthritis” (1). 
 Still described three types of the disease: 1) chronic childhood polyarthritis 
indistinguishable from adults arthritis; 2) chronic arthritis associated with systemic 
manifestations including splenomegaly, lymphadenopathy, and pericarditis; and 3) a 
disease identical to “chronic fibrous rheumatism” (1). As a consequence of Still’s 
reporting, chronic arthritis in children was assigned the eponymous designation, Still’s 
Disease. In 1946, the New York Rheumatism Association replaced the term Still’s 
Disease with the term JRA after reporting 56 cases of chronic childhood arthritis (3). 
 In 1970, a committee of the ACR proposed the first classification criteria for JRA. 
The JRA classification system was defined as arthritis in children younger than age 16 
years in one joint or more for 6 weeks or longer providing other diagnostic considerations 
were excluded. The JRA taxonomy included three subtypes, polyarticular, pauciarticular 
and systemic arthritis. The spondyloarthritis and psoriatic forms of childhood arthritis 
were considered distinct diseases and were not included in the JRA classification system 
(4, 47, 48). 
The polyarthritis JRA subgroup was defined by the number of involved joints (5 
or more); the presence of RF together with polyarthritis was considered to confer a poorer 
prognosis. RF-positive patients were older, were more likely to be female, had a higher 
percentage of antinuclear antibody (ANA)-positivity, predominant involvement of the 
small joints of the hands, a higher frequency of erosions and, in general, a poorer 
prognosis. Pauciarticular JRA was defined as arthritis in 4 or fewer joints. In general, 
pauciarticular JRA was considered to have a more favourable prognosis compared to the 
polyarticular subset. Systemic onset JRA included children with arthritis associated with 
intermittent fever and systemic manifestations such as rash, lymphadenopathy, 
hepatomegaly, splenomegaly and serositis. Systemic JRA was recognized to have 
variable outcomes with some children having a remitting relapsing course, some 
progressing to chronic polyarthritis as extra-articular manifestations waned, and in some 
children the disease remitted after a single episode (49). 
 Concurrent with the ACR classification initiative, the European League Against 
Rheumatism (EULAR) devised an alternate classification system (5). EULAR proposed 
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the term juvenile chronic arthritis (JCA) to denote children with chronic arthritis 
including those having spondyloarthropathies and psoriatic arthritis. EULAR reserved the 
term JRA for children with polyarthritis associated with RF-positivity (5). Table 2.1 
shows the comparisons between ACR and EULAR classification systems. 
 
Table 2.1 Comparison of ACR and EULAR criteria. 
 
 
The latest classification criteria for chronic childhood arthritis, JIA, was proposed 
by a subcommittee of ILAR in 1994 (50). The impetus for developing the JIA criteria 
was to establish an internationally standardized disease classification system to facilitate 
international communication and research collaborations. JIA criteria were revised in 
2004 (2) and denote a class of childhood arthritis having an unknown cause developing 
before the age of 16 years and persisting for at least 6 weeks. The JIA class comprises 
seven subgroups including 1) systemic arthritis 2) oligoarthritis, 3) RF-negative 
polyarthritis, 4) RF-positive polyarthritis, 5) psoriatic arthritis, 6) enthesitis-related 
arthritis (ERA), and 7) undifferentiated (2). The JIA subsets are defined in Table 1.1. 
Despite attempts to ensure subgroup homogeneity, some heterogeneity within JIA 
categories exists. Martini posited that the number of involved joints at onset or during the 
disease course is not a reliable criterion for defining homogenous subgroups (51). He 
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proposed that descriptors such as asymmetric arthritis, early onset age, being female, 
ANA-positivity, and uveitis should be considered as classification criteria rather than 
number of affected joints (51). Currently, children with those features tend to be clustered 
into oligoarthritis, polyarthritis or psoriatic arthritis JIA categories. Stoll et al. suggested 
that psoriatic JIA comprises two distinct subsets (52). Specifically, they proposed that 
younger children with psoriatic JIA are more likely to be female, be ANA-positive, be 
more likely to progress to polyarthritis, exhibit dactylitis and have small joint 
involvement. Older patients with psoriatic JIA are more likely to develop enthesitis, axial 
joint involvement and have persistent oligoarthritis (52, 53). 
The spondylarthropathies comprise a group of arthritis characterized by axial and 
peripheral enthesitis and arthritis, and an association with HLA-B27 (54). Although the 
spondyloarthropathies typically have their onsets during adolescence and early adulthood, 
younger children can be affected. Ankylosing spondylitis (AS) is the prototypic 
spondyloarthropathy. The spondyloarthropathy category also includes undifferentiated 
spondylitis, reactive arthritis, subsets of psoriatic arthritis, and inflammatory bowel 
disease related arthritis (54, 55). It is believed that adult onset and childhood onset AS 
represent a disease continuum with somewhat different clinical expressions; the 
childhood onset symptoms tend to include peripheral enthesitis and arthritis especially in 
lower extremities while the adult onset form presents predominantly with axial spine 
involvement (56-60). Young onset age and female sex are associated with a less 
favourable AS outcome (56, 59). The ILAR classification system considers ERA and 
psoriatic arthritis as two distinct subgroups; however, ERA and psoriatic arthritis 
subgroups can have overlapping features. Thus, some patients would be categorized as 
undifferentiated arthritis due to overlapping between categories (2). 
Childhood arthritis classification systems have been devised based on clinical 
manifestations predominantly without substantive consideration of the biologic and 
pathophysiologic basis of the conditions. As new knowledge about the underlying 
pathophysiology of childhood arthritis emerges there are likely to be new opportunities to 
refine classification criteria based on both clinical and biologically-based characteristics. 
2.2 Predictors of JIA outcomes  
JIA is the most common childhood rheumatic disease. It imposes substantial 
burden on the child’s growth and development, quality of life, and future productivity and 
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is associated with substantial burdens for families and society. A significant proportion of 
children with JIA develop permanent joint damage resulting in disability. Approximately 
half of children with JIA will have arthritis as adults (61, 62). Early identification of 
clinical and biologic characteristics that portend a poor prognosis can help direct the 
aggressiveness of initial therapy aimed at preventing joint damage and long-term 
disability. Caution must be taken in identifying patients who benefit from early 
aggressive therapy to reduce health risks of these treatments.  
A number of studies have evaluated short- and long-term JIA outcomes in relation 
to clinical remission, disability, and radiological damage. Factors such as young onset 
age, severe arthritis at onset, prolonged active disease, symmetric disease, hip or wrist 
involvement, and the presence of RF are recognized as predictors of less favourable JIA 
outcomes (30, 37, 62-69). 
The following section summarizes JIA outcome studies in relation to JIA 
categories. 
2.2.1 Systemic JIA 
Several short-term outcome studies considered the disease subtypes at onset as a 
predictive factor. In a retrospective study by Spiegel et al. early predictors of systemic 
JIA poor outcome (destructive arthritis) were identified within 6 months of disease onset. 
The outcome was measured by severity of joint damage reported by radiologists, and 
predictors included persistent systemic symptoms such as fever and thrombocytosis (70). 
The results that predicted the development of a poor functional outcome in the patients 
was validated by long-term follow-up (71). Male sex, higher number of active joints, and 
continuing disease activity were identified as risk factors for disability (72). In long-term 
and short-term studies (there is no definition of long/short-term outcome in the pediatrics 
rheumatology literature) a significant association was found between elevated levels of 
fibrin D-dimer and poor functional outcomes of systemic arthritis (73, 74). 
Modesto et al. described articular outcome in patients with systemic arthritis 
measured by Helsinki index2 (HI) and systemic symptoms of the disease. They defined 
outcomes as HI≥10 a bad articular outcome while HI<10 meant a good prognosis. The 
                                               
2 Helsinki Index is an articular index for the classification of patients with 
systemic onset juvenile chronic arthritis and is a tool for performing a quantification of 
the number of affected joints (swelling, limitation of motion).  
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onset predictors of poor outcome were presence of generalized lymphadenopathy, age<8 
years and HI>6. The presence of polyarthritis and hip involvement at 6 months were 
additional indicators of poor prognostic disease (75). 
A long-term study of systemic JIA revealed three patterns of disease course: 
monocyclic, intermittent, and persistent after 5 years follow-up. Fever and active arthritis 
at 3 months after diagnosis, an ESR>26 mm/hour, and corticosteroid use at 6 months 
were identified as predictors of a non-monophasic course. Three and 6 months after 
diagnosis, absence of active arthritis, an ESR of <26 mm/hour, and no requirement for 
corticosteroid therapy were predictors of an earlier time to remission (76).  
In systemic JIA the macrophage migration inhibitory factor (MIF)-173 
polymorphism significantly correlates with longer duration of glucocorticoid treatment, 
higher numbers of joints with active arthritis and limited range of motion, and higher 
CHAQ scores. MIF-173*C allele is identified as a predictor of poor outcome in systemic 
JIA (77). 
2.2.2 Oligoarthritis 
Historically, oligoarthritis was considered a form of JIA with a generally 
favourable long-term outcome. However, more contemporary studies have indicated that 
outcomes might not be as generally favourable as once thought (35). In one study, 
remission was defined as absence of clinical or laboratory evidence of active arthritis for 
a period of at least 6 months off medication. Thirty six percent of patients with 
oligoarticular JIA permanently remit off medication, 53% continued to have active 
disease, and 13% relapse following temporary remission (78). 
Age at onset and ANA-positivity are predictors of disability and active disease 
duration in oligoarticular JIA (68). High ESR and involvement of more than one upper 
limb joint at onset have been reported as predictive of joint damage and functional 
disability in oligoarticular JIA (35). Al-Matar et al. have shown that early involvement of 
ankle or wrist disease, symmetrical joint involvement, and an elevated ESR are predictors 
of extended oligoarticular JIA (30). 
2.2.3 Polyarthritis 
Patients with polyarthritis JIA with or without RF-positivity have high rates of 
morbidity and functional disability although RF-positive polyarthritis has a substantially 
worse prognosis than RF-negative polyarthritis. Morbidity refers to state of being 
   
 
13 
diseased or may result from adverse effects of therapies, which may impair the quality of 
life of patients and their families (79). Hyrich et al. reported in a cohort of children with 
polyarthritis JIA 64%, and 40% had CHAQ ≥ 0.75 at diagnosis and 1 year later 
respectively (80). These patients have low remission rates ranging from 0% to 5% off 
medications and 65% on medications (33). In another study remission rates of RF-
negative and RF-positive polyarthritis JIA 10 years after diagnosis have been reported as 
23% and 5%, respectively (62). 
Oen et al. have shown that male sex is the only predictor for RF-positive 
polyarthritis JIA that correlates with shorter active disease duration (68). In the same 
study male sex, older onset age, and rural residence were identified as predictors of good 
functional outcome for patients with RF-negative polyarthritis JIA (68). No HLA or 
genetic polymorphisms have been identified as predictors of disease activity in 
polyarthritis JIA. 
2.2.4 Psoriatic JIA 
Juvenile psoriatic arthritis is diagnosed when a child has arthritis associated with 
psoriasis. It can follow an oligoarticular, polyarticular or ERA pattern. The outcome of 
psoriatic JIA tends to relate to the pattern of joint involvement. Psoriatic JIA long-term 
outcome studies reveal that 70% of patients still have active disease and 1/3 have 
functional limitations 5 years after onset (81). Another study showed that after 15 years 
of disease 33% still require disease-modifying anti-rheumatic drug (DMARD) therapy 
(82) and a short-term study showed clinical remission in 60% of affected children (52). 
Flatø et al. have identifed early determinants of developing psoriatic JIA including 
history of psoriasis in the patient or in a first degree relative, dactylitis, ankle or toe 
arthritis, and HILA-DRB1*11/12 (82). Remission on medication occurs later in the 
disease course of patients with polyarthritis compared to oligoarthritis and ERA disease 
patterns (83) . 
2.2.5 Enthesitis-Related Arthritis  
ERA involves predominantly joints of the lower extremities and the axial 
skeleton. ERA is more prevalent in adolescent boys. Reported remission rates for ERA 
have varied from 17% to 60% (32, 61). Sacroiliac (SI) and axial spine involvement occur 
late in the disease course and can result in limitations in range of motion of the spine (84, 
85). Reported frequencies of SI involvement in ERA ranged from 9% to 75%. Severe 
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disability has been reported to occur in 4% to 52% of ERA patients (84). Evidence of 
sacroiliitis has been detected by dynamic MRI in 30% of children with ERA, 1 year after 
disease onset (85). 
Early and persistence hip disease, early ankle involvement, and a high number of 
involved joints during the first 6 months of the disease are predictors of poor functional 
outcome in ERA (86). Although ERA is strongly associated with HLA-B27, the presence 
of HLA-DRB1*08, and the absence of HLA-DPB1*02 are predictors of poor outcome 
(36). 
A number of studies have evaluated early predictors of outcomes of a cohort of 
JIA patients without considering the JIA subtypes. A long-term study aimed to predict 
three distinct disease outcomes 15 years after onset including: 1) remission according to 
the ACR definition of remission (26), 2) joint erosion according to radiological findings, 
and 3) physical disability based on the Stanford Health Assessment Questionnaire 
(HAQ), and CHAQ (38). Characteristics that were predictive of less favorable remission 
rates were young age at onset, HLA DRB1*08, positive IgM RF, long duration of 
elevated ESR, and large number of involved joints within the first 6 months. Predictors of 
joint erosion were early onset age, a large number of affected joints, positive IgM RF, 
long duration of elevated ESR, and symmetric arthritis. Predictors of physical disability 
were female sex, symmetric joint involvement, early hip joint arthritis, long term elevated 
ESR, and positive IgM RF (38). In a short-term study the outcome was clinically inactive 
disease according to Wallace et al. criteria (29); predictors were identified as active joint 
count, PGA, patient or parent global assessment of overall well-being, and CHAQ (69). 
2.3 Inflammatory biomarkers associated with outcomes considered in the analysis  
Genetic differences in the expression levels of a number of important biomarkers 
can lead to chronic inflammation (29). The measurement of inflammation-related 
biomarkers in body fluids and synovial tissue has provided insight into the underlying 
pathophysiology of JIA. 
Cytokines are a group of small proteins secreted by a variety of cells including 
those of the immune system. They modulate acute and chronic inflammation through 
elaborate cell signalling pathways and interactions. Cytokine is an umbrella term 
encompassing a large number of chemokines, interferons, interleukins (IL), lymphokines, 
tumour necrotizing factors (TNFs), and growth factors (87, 88). Although all cell types 
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are capable of producing cytokines, T-helper (Th) cells and macrophages are the principal 
sources (89). Three main classification systems for cytokines have been proposed. The 
first is based on their function and roles in immune response and consist of substances 
that: 1) induce cells of the adaptive immune response, 2) promote inflammation, and 3) 
inhibit inflammation (Table 2.2). The second proposed cytokine classification system is 
based on their action on target cells and include: 1) interleukins, 2) tumour necrosis 
factors, 3) interferons, 4) colony stimulating factors, and 5) chemokines (90). The third 
cytokine classification system is based on structure and specifically if an amino acid is or 
is not located between the first two cysteine residues (CXC and CC respectively) (91). In 
this review, the first and second cytokine classification systems are discussed.  
Functional genetic polymorphisms, including those mediating inflammatory 
cytokine expression, can alter the gene’s structure, function, and resultant phenotype and 
contribute to risk of polygenic diseases including arthritis (92). In the following 
discussion, SNPs that influence cytokine expression in the context of JIA are reviewed. 
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Table 2.2 Classification of cytokines by immune response. 
 
CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; GM-CSF, 
granulocyte macrophage-colony stimulating factor; IFN, interferon; 
LIF, leukaemia inhibitory factor; OPN, osteopontin; OSM, oncostatin M; TNF, 
tumour necrosis factor; TSLP, thymic stromal lymphopoietin; RANKL, Receptor 
activator of NF-kB ligand; RANTES, regulated on activation, normal T cell 
expressed and secreted. 
 
2.3.1. Pro-inflammatory cytokines 
 IL-1, IL-6, TNF-α, S100 and serum amyloid A are the most influential pro-
inflammatory cytokines in the context of childhood arthritis (90). 
2.3.1.1 IL-1 
IL-1 encompasses two distinct proteins, IL-1α and IL-1β, which are respectively 
encoded by two genes and controlled by specific inhibitors including membrane bound 
IL-1 receptor antagonist (IL-1Ra), soluble IL-1 receptor type II, and IL-1 receptor 
accessory protein (93). Monocytes, macrophages, and neutrophils, can produce IL-1 in 
response to pro-inflammatory stimuli such as cell injury, bacterial products, TNF, and 
granulocyte-macrophage colony stimulating factor (GM-CSF) (94). Also, induction of 
pattern recognition receptors (PRRs) including Toll-like receptors (TLRs) and NOD-like 
receptors (NLLs) by viral and microbial agents can lead to excessive IL-1 expression (95, 
96). The IL-1 family of proteins are produced as precursors, cleaved by the IL-1-
converting enzyme (ICE) or caspase-1 to generate active cytokine (93, 97). IL-1α 
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activates endothelial cells and macrophages, and induces production of acute phase 
reactants from the liver. IL-1β stimulates differentiation of CD4+ T cells into Th1 cells 
and Th17 cell lineages and has pyrogenic effects (98). 
The IL-1 family of proteins has nine genes located on chromosome 2 (99). Three 
IL-1 gene cluster SNPs (rs6712572, rs2071374, and rs1688075), and one IL-1 receptor 
cluster SNP (rs12712122) have been shown to be associated with risk of developing 
systemic JIA (100). Ankylosing spondylitis can be associated with IL-1A gene SNPs 
(rs1800587, rs2856836, rs17561) and these SNPs might account for ethnic variability in 
the expression of the disease (101). There are reports of IL-1 gene cluster SNP 
associations with psoriatic arthritis (102). 
Inhibiting the action of IL-1 has therapeutic benefits in certain inflammation-
mediated diseases. Pascual et al. have shown that dysregulated IL-1 production is a major 
mediator of the inflammatory cascade in systemic JIA, and IL-1 blockade with anakinra 
(recombinant IL-1Ra) is an effective treatment for the disease (16). However, response to 
anakinra among patients with systemic JIA is variable; approximately 40% have a 
favourable response while others have partial or no response (103). Ombrello and 
colleagues have shown that a variation in the IL-1RN gene influences susceptibility to 
recombinant IL-1RA therapy in systemic JIA (104). 
2.3.1.2 IL-6 
Acute and chronic inflammation induces IL-6 production by macrophages, T and 
B cells, endothelial cells, and tissue fibroblasts. The IL-6 gene is located on human 
chromosome 2 (99). Its signals are mediated by binding with IL-6 receptor, which is 
composed of two chains, IL-6R and glycoprotein 130 (gp-130). Gp-130 is a common 
signal transducing chain for other cytokine receptors. Soluble receptor of IL-6 (sIL-6R) 
also binds with IL-6, then can be attached to gp-130 (105). The pro-inflammatory 
functions of IL-6 include inducing fever, activation of endothelial cells, production of 
acute phase reactants, and B-cell proliferation. It also activates osteoclasts and promotes 
maturation of megakaryocytes, wound healing, development of Th22 and Th17, 
endothelial cell activation, fibroblast proliferation, and neuron development (106). 
Polymorphisms in the 5' flanking region of the IL-6 gene, a change from G to C at 
position 174, results in suppression of IL-6 transcription (17). 
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IL-6 and sIL-6R concentrations increase in JIA and are related to the degree of 
joint destruction (107). Levels of sIL-6R substantially increase in systemic JIA (108). It 
has been shown that in induced arthritis in mice IL-6 injection causes joint destruction, 
leucocyte aggregation, apoptosis, and T cell activation (109). Disruption of the IL-6 gene 
in knockout mice has shown that lack of this protein mitigates arthritis development 
(110). Many of the clinical features of systemic JIA such as chronic anemia, severe 
growth retardation, osteoporosis, thrombocytosis, and amyloidosis are related to IL-6 
action (111). Tocilizumab, an IL-6R antibody that blocks soluble and membrane-bound 
IL-6 receptors, is therapeutically beneficial in systemic JIA (112, 113). 
2.3.1.3 TNF 
The TNF gene-coding region is located within the major histocompatibility 
complex (MHC) class III, on chromosome 6 and includes three genes. The TNFA gene, 
encodes TNF-α; TNFB encodes TNF-β, and LTB, encodes lymphotoxin-β (114). TNF-α 
and TNF-β are similar pro-inflammatory transmembrane glycoproteins belonging to the 
TNF superfamily. TNF can be cleaved by the metalloprotease TNF-α converting enzyme 
(TACE) to form soluble TNF that may allow for more widespread cytokine effects (114, 
115). The main sources of TNF-α are activated macrophages, monocytes, B and T 
lymphocytes, and fibroblasts. Activated Th1 cells secrete TNF-β. The TNF superfamily 
consists of 20 different proteins including CD40L and RANKL. Their biological actions 
are mediated by binding to p55 and p75 (TNFRI, TNFRII) receptors. All the TNF 
receptor superfamily of ligands are capable of becoming a secreted form (116). Binding 
to the TNFRs initiates intracellular signaling leading to transcription of factors such as 
NF-kB and activation protein-1 (AP-1) that cause the production of inflammatory 
mediators and anti-apoptotic proteins (117, 118). Although TNFs usually mediate 
signalling for cell survival, the binding of TNF-α to TNFRI can result in either 
inflammation or apoptosis. Activation of caspases lead to cell death which is important 
for self-limitation of cell activation (118). The main effects of TNF are activation of 
endothelial cells, macrophages, monocytes, neutrophils, induction of the pro-
inflammatory activity of fibroblasts, and apoptosis. Similar to an endocrine hormone, 
TNF-α can circulate in blood and act at distant sites. For instance, TNF-α can stimulate 
the hypothalamus to induce fever, stimulate hepatocytes to produce acute phase reactants, 
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and promote metabolic changes leading to cachexia. TNF-α plays a major role in the 
pathogenesis of sepsis (119, 120). 
In RA and JIA patients increased levels of both TNF-α and TNF-β are detected in 
serum and synovial fluid (121). The presence of a SNP in the TNF-α gene (308 GA/AA 
and 238 GA) leads to elevation of TNF-α and increased transcriptional activity. This has 
been associated with a poorer prognosis and a lower response to anti-TNF-α drugs in 
patients with systemic JIA and RF-positive polyarticular JIA (10, 122). A genetic 
polymorphism of TNF plays a significant role in oligoarticular JIA; there is a strong 
association between the intronic 851 TNF SNP and persistence of oligoarticular JIA 
(123). Synovial tissues of patients with spondyloarthropathies, and persistent 
oligoarticular JIA express high and low levels of TNF-α, respectively. TNF-α expression 
in synovial tissues of patients with polyarticular JIA and adult-onset RA have been 
reported as intermediate. Generally, although expression of TNF-β in synovial tissues are 
low compared to expression of TNF-α in all groups, it is notably higher in children with 
polyarticular and ERA JIA (124). TNF-α levels increase in psoriatic plaques, blood, and 
in the synovial fluid of patients with active psoriatic arthritis and has correlation with 
disease severity (9, 125-127). There is an association of TNF-α promoter polymorphism 
at position -238 with psoriasis and psoriatic arthritis (128). In patients with AS, TNF-α, 
TNFRI, and TNFRII levels are high. After treatment with TNF blockade agents the level 
of TNFRI falls. In the sacroiliac joints of AS patients abundant TNF-α mRNA near the 
site of new bone formation can be detected (129). 
The significant role of TNF in the pathogenesis of RA has made it an important 
target for therapy. Anti-TNF therapy is an effective treatment choice in polyarticular JIA 
patients not responsive to methotrexate (130). An effective strategy to inhibit TNF-α 
action is to use monoclonal antibodies to block its membrane-bound or soluble receptors 
(131). Infliximab and adalimumab are chimeric IgG anti-TNF-α monoclonal antibodies 
that bind to both membrane-bound and soluble TNF-α receptors (132, 133). However, 
development of neutralizing antibodies against infliximab and adalimumab can reduce 
the clinical efficacy of the treatments (134-136). Etanercept, a soluble TNF receptor, is 
the extracellular portion of the human p75 TNF-α receptor fused to the Fc portion of 
IgG1 (137, 138). Etanercept binds to both TNF-α and lymphotoxin-α, a member of the 
TNF family that also activates the inflammatory pathway through the TNFRs (139). 
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Etanercept does not have the potential to induce the formation of neutralizing antibodies 
(137). 
High rates of treatment failure with TNF inhibitors have been reported in systemic 
JIA (140, 141). ERA subtype patients with peripheral disease who do not respond to 
DMARDs and those with axial involvement have shown clinical response with anti-TNF 
inhibitors (142, 143). Psoriatic JIA patients with inadequate response to DMARDs, axial 
disease, dactylitis and enthesitis are candidates for TNF inhibitor therapy (144). TNF 
inhibitors are indicated for intractable cases of oligoarticular JIA unresponsive to non-
biologic treatment approaches (143). 
2.3.1.4 S100 
The S100 protein family comprises the largest subgroup within the Ca2+-binding 
EF-hand (helix E-loop-helix F) protein group (145). Only vertebrates possess S100 genes, 
which are clustered at chromosome 1q21 and 21q22. Twenty-five proteins have been 
identified as belonging to the S100 family. They are small molecules, about 10-12kDa, 
classified into 3 subgroups: 1) proteins which exert intracellular regulatory effects, 2) 
those with intracellular and extracellular functions, and 3) those with only extracellular 
regulatory effects (146). 
S100 protein can be expressed intracellularly in pathological states while they are 
absent in normal physiological conditions of the cell. Their expression patterns vary 
among different S100 proteins (147). These proteins regulate cell proliferation, 
differentiation, apoptosis, Ca2+ homeostasis, energy metabolism, inflammation and 
migration/invasion through interactions with other proteins. S100 proteins derived from 
cells of myeloid origin are suggested to be new markers of inflammation (145, 146). A 
subgroup known as calgranulins including S100A8, S100A9 and S100A12 (also termed 
phagocyte-specific S100) are highly expressed in monocytes and granulocytes and have 
been associated with acute and chronic inflammation (148). They are pro-inflammatory 
mediators when appearing extracellularly. Cryopyrin-associated periodic syndromes, 
familial Mediterranean fever (FMF), hyper-zincemia and hyper-calprotectinemia, 
polyarticular JIA, and systemic JIA are autoimmune diseases associated with over 
expression and dysregulation of calgranulins (149-152). 
Increased intracellular calcium concentration stimulates activation of 
macrophages. Calcium ions initiate changes in calcium-binding proteins (S100A8, 
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S100A9, and S100A12), which interact with intracellular target structures (153). 
Expression of S100 proteins in monocytes and macrophages is tissue specific and occurs 
only during the early stages of cell differentiation (154). In humans, S100A8 and S100A9 
assemble as an S100A8/S100A9 heterodimer (155). The distribution of S100A12 in the 
cytoplasm of granulocytes is similar to S100A8/S100A9, but it is less abundant (156). 
Intracellular calcium signaling induces S100A12 protein independent of S100A8/S100A9 
(157). These proteins are released by stimulated phagocytes partly in response to calcium 
mediated signaling (158). The first cells targeted by released phagocyte-specific S100 are 
cells within the endothelial layer. The binding of S100A8/S100A9 and S100A12 to the 
surface receptors induces various intracellular inflammatory signaling pathways and 
recruitment of more leukocytes (159, 160). Besides their intracellular effects, S100A 
proteins activate immune cells. S100A8/S100A9 enhance adhesion of neutrophils to 
endothelial cells (160). S100A12 exerts chemotactic effects on phagocytes, up-regulates 
expression of TNFs and IL-1, and increases release of IL-2 (159). Their cytotoxic effects 
influence the survival or growth of inflammatory cells and homeostasis. S100A8 and 
S100A9 have direct roles in synovial inflammation and auto-immune disease (151). 
Induced arthritis in animal models indicates a direct role of phagocyte-specific 
S100 proteins in synovitis (161). Accumulation of S100A8 and S100A9 expressing 
macrophages in the cartilage surface suggests correlation between them and signs of 
cartilage destruction and direct role of S100A8 and S100A9 in the destructive process of 
inflammatory arthritis (162). It also has been shown that S100A12 induces synovial 
inflammation in mice with collagen-induced arthritis (163). Cytokine production and 
MMP’s activation within the synovium depend on interaction of S100A12 with its 
receptors (163, 164). 
S100A8 and S100A9 were first identified in the context of RA. Activated 
phagocytes expressing S100A8, S100A9 proteins are abundant in inflamed synovium 
specifically at cartilage destruction and bone erosion sites (165). Synovial fluid 
concentration of S100A8/S100A9 is 10-fold higher than their serum levels in individual 
patients with inflammatory arthritis (166). The correlation of serum S100A8/S100A9 
concentrations with the arthritis activity and their diagnostic capacity as a marker of 
synovial inflammation has been confirmed in RA patients (167, 168). Similarly, serum 
levels of S100A12 correlate well with disease activity (169). S100A12 increases in the 
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synovial fluid and serum of RA patients while it is undetectable after successful treatment 
and in patients with osteoarthritis (169, 170). 
Phagocyte-specific S100 proteins have also been detected in serum and synovial 
fluid of JIA patients (171). Similar to RA patients, the serum concentrations of these 
proteins can be considered as markers of disease activity in childhood arthritis (172). In 
JIA patients who are judged to have inactive disease by clinical indicators elevated levels 
of S100A8/S100A9 or S100A12 represent that they are at risk for disease flare (171). 
Systemic JIA patients have notably high expression and serum concentrations of 
S100A8, S100A9 and S100A12 than other JIA subtypes (20-fold higher) because of 
massive neutrophil activation (171). In addition, these patients show extensive expression 
of S100A8/S100A9 in the dermal epithelium (172). Therefore, S100A8/S100A9 and 
S100A12 can be considered as the tool to help differentiate systemic JIA from systemic 
infections. Potentially, phagocyte-specific S100 proteins might be appropriate targets for 
new anti-inflammatory therapies. 
2.3.1.5 Serum amyloid A 
Serum amyloid A (SAA) is a heterogeneous family of proteins which behave as 
acute phase reactants, and are associated with high density lipoproteins (173). The human 
SAA consists of 104 amino acid residues with six main isoforms as products of four 
active genes SAA1, SAA2, SAA3, and SAA4 in the short arm on chromosome 15 (174). 
SNPs in SAA1 are related to 5 isoforms of SAA1 (SAA1.1 - 1.5), which are associated 
with FMF, coronary artery diseases, cerebral infarction, and osteoporosis and arthritis 
related amyloidosis (175, 176). SAA1and SAA2 genes can be activated during acute-
phase responses (177). IL-1β, IL-6, TNF-α, and glucocorticoids stimulate expression of 
the SAA1 gene in hepatocytes. Acute-phase SAA genes expression involves the 
transcription factors C/EBP, NF-κB, AP2, SAF, Sp1 and STAT3. SAA1 is recognized as 
a clinical indicator for inflammation (178). 
Plasma levels of SAA1 and SAA2 increase dramatically during inflammation and 
consequently are useful biomarkers of inflammation (179). In JIA patients serum levels 
of SAA1 increase significantly with a strong positive correlation with the number of 
active joints (180). Scheinberg, et al., showed that SAA levels are high in children with 
polyarticular and systemic JIA and increase during disease exacerbation, and decrease 
during disease remission and after prednisone therapy (181). An adult study has shown 
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that the serum level of SAA may be a better biomarker for RA disease activity than CRP, 
especially during treatment with TNF antagonists (182). Elevated levels of A-SAA in 
synovium of RA patients is associated with increased cartilage degradation (183). These 
findings support SAA as an indicator of disease activity and outcome predictor in chronic 
arthritis 
2.3.2 Anti-inflammatory cytokines 
Anti-inflammatory cytokines control the pro-inflammatory cytokine response 
including specific cytokine inhibitors and soluble cytokine receptors. They have a crucial 
role in modulating the inflammatory process (99). 
2.3.2.1 IL-10  
IL-10 is a homodimer protein (consisting of two identical molecules), mIL-10 and 
hIL-10, encoded by the IL-10 gene located on chromosome 1 near the IL-19 and IL-20 
genes (184). The protein is produced by activated Th2 (helper CD4+), Tc2 (cytotoxic 
CD8+), Tr1 (regulatory T cell), B cells (185). Other cell types that produce IL-10 are, 
lymphocytes, monocytes, macrophages, and mast cells (99). The IL-10 receptor has two 
chains (IL-10R1 and IL-10R2) related to the interferon receptor (IFNR) family (186). 
IL-10 plays multiple roles in immune-regulation and inflammation. It suppresses 
the expression of TNF-α, IL-6 and IL-1, up-regulates endogenous anti-cytokines and 
down-regulates pro-inflammatory cytokine receptors (187). It stimulates B-cell survival 
and antibody production, while inhibiting Th1 and Tc1 development. IL-10 also inhibits 
production of pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6, and TNF; 
chemokines such as monocyte chemoattractant protein (MCP)1, MCP5, RANTE, 
macrophage inflammatory proteins (MIP)s; and growth factors such as GM-CSF, and 
granulocyte-colony stimulating factor (G-CSF) (187, 188). IL-10 gene polymorphisms 
are associated with inflammatory diseases including JIA (189), Behçet’s disease, uveitis, 
systemic lupus erythematosus (SLE) (190), RA, B-cell lymphoma, gastric cancer, and 
Type 1 diabetes (191-193). Three SNPs in the promoter region of IL-10 at positions -
1082(G/A), −819(C/T), and −592(C/A) have been identified (194). A SNP in the IL-10 
gene promotor at position -592 increases the risk of developing JIA (187, 195). The G 
allele at the −1082 position has a negative association with JIA (196). In systemic JIA a 
low expression of IL10-1082 has been reported (197). 
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The important anti-inflammatory effect of IL-10 is to inhibit IL-1 and TNF 
production as they have synergistic and amplifying effects on the inflammatory processes 
(198, 199). In RA synovial macrophages and T cells produce IL-10 to inhibit production 
of inflammatory cytokines by synovial cells (200). In animal models of RA, IL-10 
reduces clinical manifestations of the disease and suppresses cytokine production (201). 
Because of the potential effects of IL-10 in suppressing inflammation, targeting IL-10 
therapeutically has been considered for treatment of chronic inflammatory diseases. 
(202). 
2.3.3 Adaptive immunity 
Genetic background and environmental exposures interact through adaptive 
immune system responses. Adaptive immunity includes humoral and cell-mediated 
immunity. T cells produce adaptive immune cytokines after being exposed to a specific 
antigen. 
2.3.3.1 IL-2 
IL-2 is important for the proliferation of T and B lymphocytes and natural killer 
(NK) cells (203). The IL-2 gene is located on chromosome 4 near the gene that encodes 
IL-21, and has only one allele (204). It is secreted primarily by activated T cells (CD4+ 
Th0, CD4+ Th1, and CD8Tc1) and dendritic cells (205). The IL-2 receptor has three 
subunits α (CD25), β (CD122), and γ (CD132). The gamma subunit is shared by IL-4R, 
IL-7R, IL-9R, IL-15R, and IL-21R. While assembly of the three chains results in a high 
affinity receptor, integration of two chains (β and γ) produce a receptor with medium 
affinity (206). Defects in IL-2/IL-2R profoundly affect cell-cell interactions and cell 
death when the immune system responds to antigens (207). Congenital lack of the gene 
encoding IL-2R γ chain causes X-linked severe combined immunodeficiency (SCID) 
(208). The IL-2Rα and IL-2Rβ and a SNP in the IL-2IL12 region (rs1479924) have been 
identified as a susceptibility loci for oligoarticular or RF-negative polyarticular JIA. 
(209). These findings suggest a vital role for the IL-2 pathway in JIA pathogenesis. 
2.3.4 Matrix metalloproteinases 
MMPs are zinc-dependent proteolytic enzymes. They are members of the 
metzincin group of proteases, which share structurally similar domains, in particular the 
zinc dependent catalytic domain and the activation peptide (pro-domain). In humans, 
there are 24 MMP genes that are expressed as inactive pro-proteins. To activate the 
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protein, the pro-domain is cleaved from the catalytic domain (139). The regulation of 
MMPs is controlled partly by cytokines, growth factors and tissue inhibitors of 
metalloproteinases (TIMPs) (210). MMPs participate in tissue remodelling by degrading 
extra cellular matrix. Important biological processes can be regulated by MMPs including 
cell migration, cell differentiation, growth, inflammatory processes, neovascularization 
and apoptosis, processes all operative in the context of arthritis (211). 
Most MMPs are expressed in synovial tissue of RA patients predominantly MMP-
1, MMP-9, MMP-13, MMP-14, and MMP-15. They are responsible for synovial 
remodelling and inflammatory tissue destruction (212). MMP-3 is associated with RA 
disease activity, cartilage breakdown (213), and is a predictor of radiographic disease 
outcome in RA patients (214). Elevated serum levels of MMP-3 are found in patients 
with active ankylosing spondylitis (215). Excessive expression of MMPs and low 
expression of TIMP-1 have been detected in the synovial tissue of JIA patients (210, 
212).  
Production of MMP-3 and MMP-1 can be induced by IL-1 and TNF in arthritis; 
thus, these cytokines increase cartilage degradation by inducing collagen-degradation 
mediators MMP-3 and MMP-1 (216). Gottorno et al. reported a significant increase in 
MMP-3 and MMP-1 in synovial fluid of patients with JIA (217). Peake et al. suggested 
that increased synovial fluid level of MMP-1 is consistent with inflammatory activity in 
the joint in all JIA subtypes (218). They suggested that degradation of type II collagen 
occurs early and continues throughout the disease course and that serum MMP-3 is a 
biomarker of active arthritis in JIA (218). Taken together, identifying the increased 
expression of some MMPs in RA/JIA synovial tissue and serum may provide a biomarker 
of diagnostic, prognostic, and therapeutic relevance. 
MMP inhibitors have been synthesized (zinc-binding globulins [ZBGs], non-
ZBGs inhibitors) for management of osteoarthritis, cancer, and cardiovascular disorders 
but they exert undesirable musculoskeletal side effects. Gene based therapies of TIMPs 
are being assessed in animal models (219). 
In summary, the available evidence shows that dysregulation and imbalance 
between pro- and anti-inflammatory biomarkers are important factors in JIA 
pathophysiology. Growing understanding of the immune and inflammatory pathways in 
JIA has led to development of new medications that target inflammatory cytokines. As 
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examples, inhibitors of IL-1, IL-6 and TNF-α have substantially changed the outcome of 
JIA in systemic and polyarthritis subtypes. Future opportunities will be to recognize 
specific cytokines as markers of disease activity and attributes that aid in developing 
biologically-based classification and a more personalized approach to diagnosing and 
managing individual patients. 
2.3.5 Gene and HLA characteristics in JIA 
Multiple HLA alleles, different from those in RA patients, are associated with 
JIA. The reported associations include HLA-B27 with ERA, HLA-DRB1*01, DRB1*08, 
DRB1*11, DRB1*13, DPB1*02 and DQB1*04 with oligoarticular JIA (220, 221), HLA-
DRB1*08 and DPB1*03 with polyarticular RF-negative JIA and DRB1*04, DQA1*03, 
and DQB1*03 polyarticular RF-positive JIA (221-224). HLA-DRB1*01, 
and DQA1*0101 are associated with psoriatic arthritis (221), and HLA-DRB1*04 with 
systemic JIA (224). HLA-DRB1*04 and DRB1*07 have been reported as protective 
genes for oligoarticular JIA, and DRB1*18:01 and DQB1*06:02-8 have been reported to 
be protective for all JIA groups (220-222, 225). 
Gene expression and genome-wide genotyping have identified loci outside the 
HLA gene complex associated with different JIA subtypes, particularly PTPN2, PTPN22, 
STAT4, ANKRD55, IL-2, IL-2RA, IL-21, and SH2B3-ATXN2. The functions of these 
genes are chiefly regulating production and function of inflammatory biomarkers and 
their receptors. For instance, the PTPN2 gene modulates the expression of IL-2, IL-4, IL-
6, and IFN. SNPs related to PTPN2 (rs7234029 (A>G), and rs2847293 (T>A)) cause 
impairment in the regulation of inflammatory pathways including joint inflammation 
(226-228). 
Association between early onset oligoarticular and persistent oligoarticular JIA 
with TNFA, the gene encoding TNF-α, have been reported (123, 229). Systemic JIA is 
associated with a SNP at position -857 of TNFA (230). TNFA variant is also associated 
with polyarticular JIA (231). In Norwegian children a SNP in the promoter region of IL-
1A, the gene encoding IL-1α, has been shown to be associated with early onset 
oligoarticular JIA (232). A SNP in the promoter of the IL-6 gene, several variants of the 
IL-1 gene, and IL-1R gene clusters are associated with systemic JIA (17, 100). An 
association between JIA and PTPN22 C1858T has been identified in Norwegian, Czech, 
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and British patients (233-235). Lymphoid tyrosine phosphatase (LYP), which inhibits T-
cell activation, is regulated by the PTPN22 gene (236). 
2.4 JIA outcome measures 
Three major outcomes were investigated in earlier outcome predictor studies 
including remission, physical function or health status, and joint damage (33, 62, 237, 
238). However, there has been some inconsistency in outcome definitions. Remission 
criteria are influenced by the classification system applied. Time from disease onset to 
study enrolment and last follow up visit contributes to variability in outcome study 
protocols making it difficult to precisely compare studies. 
Physical function outcome is conventionally measured with specific tools, such as 
HAQ, CHAQ, JAQQ, or Steinbrocker functional class (239-242). HAQ, a measure of 
function in adults, consists of 100 questions with five principal dimensions (death, 
disability, discomfort, drug toxicity, dollar cost), which have been separated into several 
components. Functional ability is measured by nine components (dressing and grooming, 
arising, eating, walking, hygiene, reach, grip, outside activity, and sexual activity). Each 
question is scored from 0 to 3 where 0=without any difficulty, 1=with difficulty, 2=with 
some help from another person or with a device, and 3=unable to do. The index is 
calculated by averaging the scores. The other indices also range from 0 to 3. In the dollar 
cost section, annual medical and surgical costs are calculated. HAQ can be either self or 
interview administered (240). 
CHAQ, an adaptation of the HAQ for use in children, is an effective, valid, and 
reliable tool to assess childhood arthritis (239). CHAQ evaluates performance of the 
child’s activities in their daily environments. CHAQ is designed for children from 1-19 
years old and includes 38 items grouped into 8 domains including physical function, 
dressing and grooming, arising, eating, walking, hygiene, reach, grip, activities, a pain 
index, and health status index (overall health status). CHAQ scores items are from 0-3, 
indicating the magnitude of child difficulty in performance of daily activities during the 
past week (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 
3=unable to do) although pain and health status indices are scored on a 10 cm visual 
analogue scale. CHAQ data is acquired by self-report interview of children ≥ 8 years old, 
or a parent report for children younger than age 8 (239, 241, 243). 
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JAQQ is an instrument to assess the health-related quality of life in children with 
arthritis. It measures physical functioning, emotional well-being, and an array of general 
symptoms of quality of life in children aged 2-18 years old. JAQQ includes 74 items 
grouped into four domains including gross motor function, fine motor function, 
psychosocial function, and systemic or general symptoms. In the revised version of 
JAQQ a pain scale of 10 cm VAS has been added. JAQQ is self/parent-administered 
questionnaire with each item rated from 1 to 7 (244, 245). 
The Steinbrocker classification is a method for categorizing functional capacity of 
patients with RA (246). In 1991, ACR revised the Steinbrocker functional classes as 
follow: Class I=able to perform usual activities of daily living (self-care, vocational, and 
avocational); Class II=able to perform usual self-care and vocational activities, but 
limited in avocational activities; Class III=able to perform usual self-care activities but 
limited in vocational and avocational activities; Class IV=limited in ability to perform 
usual self-care, vocational, and avocational activities (247). 
Anatomical bone and joint outcomes are determined mainly by radiographic 
assessment of joints (63). Reported structural outcomes include joint erosion, joint space 
narrowing, and ankyloses. The radiological findings, similar to remission rates, are 
influenced by the duration of the disease. 
Most JIA prediction studies have been retrospective outcome studies. They are 
difficult to compare as different classification criteria have been used and duration of 
follow-ups have varied. New medications and treatment strategies have changed the 
disease outcome substantially, thus the results of earlier long-term studies may no longer 
be relevant in the context of contemporary therapies (248, 249). There are limited number 
of studies that have reported the role of an array of inflammatory biomarkers as 
predictors of disease outcome. 
2.5 Overview of statistical analyses methods used in this research 
In this section an overview of the application of data mining in medicine and 
select data mining methods including cross-validation, data reduction and feature 
selection, a clustering method, and a classification method are discussed.  
2.5.1 Data mining and its application in medicine 
Coincident with increasing knowledge about JIA pathophysiology and 
accumulating biologically-based data, methods and tools for analyzing large datasets 
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have emerged. Data mining is one approach that can help interpret large, complex 
clinical-biologic datasets in JIA. 
Machine learning, a computer science statistical framework that automates the 
generation of models, can help distill useful information from large amounts of complex 
data. It has been described by Mitchell as: “a computer program is said to learn from 
experience E with respect to some class of tasks T and performance measure P if its 
performance at tasks in T, as measured by P, improves with experience E” (250). 
Data mining is the process of discovering meaningful hidden patterns within data 
by applying machine learning techniques. Basic concepts in data mining are description 
and prediction. By finding useful patterns in a substantial amount of information it is 
possible to make predictions. There are two data mining methods: unsupervised 
(description approaches) and supervised (prediction approaches). Unsupervised methods 
include clustering and association rules; supervised methods include classification and 
regression. The goal of clustering approaches is to find naturally occurring, interpretable, 
rational patterns, and associations within the data, while the aim of classification is to 
construct predictive models (254, 255). Association rules are if/then statements that 
explore the relationships among variables. 
 Medicine, like other fields of science, can take advantage of such machine 
learning approaches. Diseases are mainly categorized (classified) according to their 
measurable signs and symptoms. For example, an inflamed joint can be described based 
on the size of an effusion, degree of joint warmth or redness, range of motion, and 
associated pain without considering the underlying pathophysiologic process that gave 
rise to the inflammation. Considering inflammatory biomarker profiles in individual 
patients could inform patient-specific, biologically-based personalized approaches to 
targeted therapies. In fact, applying supervised learning methods to an integrated 
biological, genetic, environmental, and clinical dataset could help develop a completely 
new disease taxonomy that can direct individual patient treatment options.  
Machine learning and data mining have provided a unique opportunity for 
medical scientists to investigate new disease taxonomy leading to accurate diagnosis, 
targeted therapy, and improved outcome. 
Predictive data mining can help solve important problems in research and clinical 
medicine. By applying predictive data mining, clinicians can use patient information to 
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predict the course and outcome of disease. Predictive data mining has received great 
attention in molecular biology and is routinely applied in genomic medicine (256). The 
majority of predictive genomic studies are related to oncology. In particular, early 
diagnosis of acute myeloid leukemia and acute lymphoblastic leukemia has dramatically 
altered patient treatment and outcome. This approach has provided a cancer classification 
strategy based on only gene expression, which is important for outcome prediction in 
cancer treatment (257-259). 
Combining clinical and gene expression data with unsupervised and supervised 
learning can further improve classification accuracy and the clinical relevance of the 
prognostic models (260, 261). 
2.5.2 Data pre-processing 
Raw data are generally incomplete as they can contain missing values, errors, and 
outliers, and are susceptible to inconsistency. Prior to applying data mining methods data 
pre-processing is highly recommended, which encompasses techniques that transform raw 
data into an understandable format from both numerical and visual standpoints. In data 
mining a variable is called a feature. For example, for a child with arthritis the features 
can be listed as number of active joints, sex, age, ESR, and CRP. In this research, 
variable and features are used interchangeably. Prior to discussing some data pre-
processing techniques, it is necessary to understand an important concept known as cross-
validation.  
2.5.2.1 Cross-validation 
Cross-validation (CV) is a commonly used method in data mining and statistics to 
evaluate models and involves assessing how the results of the analysis will generalize to 
an independent dataset. Typically, analysts perform k-fold CV or leave-one-out CV 
(LOO-CV). In k-fold CV the dataset is randomly split into k mutually exclusive subsets 
of approximately equal size (251, 252). A model is trained using k-1 subsets (called 
traning sets), and is validated on the remaining part of the data (known as test sets). The 
process repeats k times. The overall accuracy of the model is calculated by averaging the 
performance measures over k-folds (252). A common value of k is 10 (253). In LOO-CV, 
at each iteration one observation or one variable is left out from the training set, and the 
trained model is tested on the one observation or variable that is left out. At the end, 
overall accuracy of the model is calculated as described above. 
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2.5.2.2 Dimensionality reduction, principal component analysis 
In statistics, data dimension refers to the number of variables. High dimensional 
data means that the number of variables is high and can exceed the number of 
observations. There are two fundamental issues associated with multidimensional data: 
noise and redundancy. Big data can include large amounts of meaningless information 
known as noise. Noise may be introduced into a variable due to human error such as 
reporting a subject age as -40. Alternatively, a variable might be a noise. As an example, 
when evaluating half-life of a drug, weight and height should be removed from the data 
when body mass index is calculated. Noisy data may provide worthless results with poor 
accuracy. Redundancy means that the variables are highly correlated. Redundancy issues 
produce the same information from different points of view and increase the number of 
degrees of freedom. High dimensionality in a dataset can also make the data difficult to 
visualize and analyze.  
To understand large data, dimensionality reduction methods should be applied 
(254). In multidimensional datasets there are sets of variables that are uncorrelated with 
each other, while the variables within each set are correlated with one another. A set of 
correlated variables can be combined and become a single new variable (255).  
PCA, a well-known data reduction method, is a descriptive mathematical 
procedure introduced in 1901 by Pearson and later by Hotelling, that extracts important 
variables (in the form of a new set of variables called principal components [PCs]) from a 
large set of variables (256, 257). PCA extracts low dimensional sets of data with the aim 
of capturing as much information as possible.  
This technique increases interpretability of the dataset while at the same time 
minimizing information loss. With fewer variables, analysis and visualization become 
more meaningful. To preserve as much variability as possible, data are transformed 
linearly. Thus, two assumptions of PCA are: 1) variables should be linearly related to 
each other, and 2) variables should be correlated to each other to some degree (258). The 
transformation steps are an iterative procedure to identify combinations of variables with 
maximum variance and minimum correlation. The eigenvalues and their corresponding 
eigenvectors are the means for linear transformation of the data. Eigenvectors are the 
axes (directions) along which a linear transformation performs stretching/compression 
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changes, and eigenvalues (denoted by λ) are the scalers by which the 
stretching/compression occurs (259). 
 
 
 
Figure 2.1 A schematic illustration of PCA analysis. 
Multidimensional data reconstructed in 2 dimensions. Each vector represents an 
eigenvector. The PC1 (red arrow) has higher variance than the PC2 (blue arrow). The X1 
and X2 axes are geometrical coordinates.  
 
The original data is rotated to find the new axes (eigenvectors) with new 
coordinates that indicate directions of highest data variance. The axes or new variables 
are PCs and ordered by amount of their variance (maximum to minimum). The first 
component, PC1, represents the direction of the highest variance of the data; the second 
PC represents the highest remaining variance orthogonal to the first component and so 
forth. In PCA terminology, eigenvectors are termed loadings, and each loading represents 
one component. The eigenvectors corresponding to the largest eigenvalues are the PCs 
with the highest variance of the data (260). 
For visualization, the first and second component can be plotted against each 
other to obtain a two-dimensional representation of the data that captures most of the 
variance (assumed to be most of the relevant information). That approach is useful to 
analyze and interpret the structure of a dataset (Figure 2.1). Consider a dataset having a 
number of HLA and gene associations in a group of adult and child patients with chronic 
inflammatory arthritis. Applying PCA reveals the cluster of HLA and genes of children 
and adult patients localized to the same PC suggesting an adult counterpart of JIA based 
on the  genetic information  related to the disease. As an example, consider that PC1 
consists of HLA and genes from children who have developed the following subtypes of 
JIA: extended oligoarticular, polyarticular RF-positive, and psoriatic arthritis, together 
X1 
X2 
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with adults who suffer from polyarthriticular disease. PC2 retains genetic information of 
persistent oligoarticular, and polyarticular RF-negative JIA along with genetic 
information of adults with the same condition.  
Therefore, PCA analyses create a new dataset of new variables while retaining the 
important information of the original set. Although PCA has been widely used in genetic 
studies, it has several limitations. Lack of probabilistic components in PCA confines the 
potential to extend the scope of application of PCA. As an example, PCA cannot be 
applied to nominal and ordinal data and does not work well when handling data that is 
too sparse. It has been shown that the PCs with the larger eigenvalues do not necessarily 
contain more information (261). The assumption of linearity of relationships among 
variables is another constraint. Finally, the inability of PCA to deal with missing data 
restricts its application (256). The shortcomings of PCA can be addressed by integrating a 
probabilistic approach, resulting in probabilistic PCA (PPCA) (262). In PPCA, the 
expectation maximization (EM) algorithm estimates the model parameters (for example, 
mean) through estimation of latent variables within the data, which can deal with missing 
data (263). The maximum likelihood of the latent variables is equivalent to the principal 
eigenvectors of conventional PCA (262). EM is described later in this chapter. 
An important question is how many PCs should be retained in order to account for 
most of the variation in the dataset? As eigenvalues are ordered they can be truncated; 
that is, the first few principal components that account for a desired amount of variance in 
the original data can be selected. There is no definite method for selecting the number of 
PCs. One way is to represent the data in scree plot of eigenvalues (264). Figure 2.2 shows 
a scree plot with the number of eigenvalues ordered from biggest to smallest. The 
optimum number of components is the number that appears prior to the sharp change in 
the plot (the elbow) (264). 
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Figure 2.2 Scree plot. 
A scree plot displays all eigenvalues in their decreasing order. The appropriate number of 
components prior to the elbow is 3. 
 
 Another method for selecting the optimal number of PCs is calculating a Q#	index. Q#	is an index that estimates the external prediction capability of a model and 
can be used for selecting the number of PCs. The basis of Q# is similar to computing the 
goodness of fit (coefficient of determination) or R2 in regression models. Because of the 
mathematical properties of R2, as the number of factors which can be variables (even 
noisy ones) increases, the R2 value increases and therefore it cannot be a criterion for a 
model’s predictive capability (it measures the strength of the least-squares fit to the 
training set). An R2 value of 0.7 means that the model accounts for 70% of the variance 
for the training set. Q#	is the R2 value calculated from applying the model to the test set 
instead of the training set and it may or may not increase when more factors are added. It 
has a value between 0 and 1; the higher the	Q#, the closer the reconstructed data is to the 
original data (Figure 2.3) (265-267). It can be interpreted as the ratio of variance that can 
be predicted independently by the PCA/PPCA. In another words, low Q#	indicates that 
the PCA/PPCA model only describes noise and that the model is not a true representative 
of data structure.  
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Figure 2.3 A Q2 plot. 
Q2 plot, the goodness of prediction, (defines the average error of prediction) used for 
internal cross-validation which allows optimising the choice of number of PCA loadings. 
In this graph, the appropriate number of PCs is 3. 
 
2.5.2.3 Feature selection 
High-dimensional data increases the risk of over-fitting3 and cannot provide 
statistically meaningful results due to irrelevant, redundant and noisy data (268). Feature 
(variable) selection (FS) techniques are essential steps of data pre-processing. FS 
algorithms attempt to project the original data, which has a large number of features and a 
small number of subjects, onto a smaller number of variables while preserving as much 
information as possible (269). FS accelerates learning processes, reduces storage space, 
facilitates data visualization and understanding, and decreases data dimensionality, which 
improves prediction accuracy (270).  
Many FS techniques have been developed for machine learning and can be 
categorized into filter and wrapper methods (271). Filter methods are heuristic, fast, and 
utilize the general characteristics of the data. In comparison, wrappers use learning 
algorithms to evaluate the utility of feature subsets. Two filter-based approaches that have 
                                               
3 Overfitting is a modeling error that occurs when an algorithm fits all or the most 
of data for the training set, even noise, to generate the model. Thus, the model has high 
accuracy for a classifier when evaluated on the training set but low accuracy when 
evaluated on a new test set. 
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been used in this research are correlation-based feature selection (CFS) and ReliefF. Both 
are multivariate methods that consider relationships among the features (268). 
CFS is based on the rationale “a good feature subset is one that contains features 
highly correlated with the class variable (in prediction problems), yet uncorrelated with 
each other” (272), and assesses the features’ redundancies by use of a correlation that 
evaluates the predictive ability of subsets of features (273). The algorithm first 
standardizes variables and then computes correlation coefficients within various 
composites of variables, and between composites and class variables. The final result is a 
composite of variables with low inter-correlations, which in turn is highly correlated with 
the class variable (272). 
ReliefF, a multivariate algorithm based on a statistical method instead of heuristic 
searches, is an instance (observation)-based learning algorithm. In a binomial class 
variable problem, the algorithm first draws an observation randomly from the training 
data, and then computes Euclidean distance4 between the observation and the nearest 
observation of the same class (nearest hit) and a different class (nearest miss). After m 
iterations, the last step is to give high weight to the feature that discriminates between the 
nearest miss and the observation while it has the same value for the nearest hit. The only 
limitation of ReliefF is the inability to recognize redundant features (274). 
2.5.3 Clustering 
Clustering is an unsupervised pattern recognition method that distributes a set of 
observations into subsets, denoted as clusters. The goal of clustering algorithms is 
partitioning the data where a collection of observations within a cluster is similar within 
the cluster but dissimilar between clusters (275). 
There are two distinct clustering methods, hard and soft (276). In hard clustering 
each observation belongs only to one group, and there is no overlap among clusters. In 
soft clustering, groups can overlap and a single individual can fall into more than one 
group with different degrees of belonging. In other words, a single observation could be 
in several groups at the same time with different probabilities. K-means and Gaussian 
Mixture Model (GMM) are examples of hard and soft clustering methods, respectively 
                                               
4 The Euclidean distance between two points measures the length of a straight 
segment connecting the two points. 
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(276). In soft clustering probability measures identify the observations which belong to a 
cluster. In this thesis, the GMM soft clustering algorithm was used. 
2.5.3.1 Gaussian Mixture Model 
GMM is a common clustering method; it is alternatively referred to as 
expectation-maximization (EM) clustering based on optimization strategy. The Gaussian 
(normal) distribution is bell-shaped. Mean and standard deviation are two characteristics 
of a probability distribution. The Gaussian distribution formula is termed the probability 
density function. Using the formula, for a given event X, the associated Y values can be 
computed, which are the probabilities for X values. GMM refers to multiple Gaussian 
distributions of multiple hidden bell-shaped curves (277). For a set of events from a 
distribution with unknown parameters (mean, SD), the probability that an individual 
event belongs to a specific Gaussian distribution can be computed. The solution to 
estimate the parameters of the hidden Gaussian distributions is given by the EM 
algorithm. EM is an iterative mathematical optimization that can compute the maximum 
likelihood of hidden parameters given observed data points. Each hidden Gaussian 
distribution represents a cluster in the data (278) (Figure 2.4). 
GMM can determine the maximum likelihood estimates of all the distributions’ 
means. If the means are known, then the probability of each data point belonging to one 
or the other Gaussian distributions can be determined. Thus, the clusters within the data 
are revealed. 
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Figure 2.4 Gaussian mixture model. 
Two distributions within a dataset are plotted using means and standard deviations (upper 
graph). GMM starts with initial guesses for means (A), determines the new estimate of 
means (B), and iterates (C) until convergence (D). Axes are gemetrical co-ordinates. 
(Figure inspired by Ihler: https://www.youtube.com/watch?v=qMTuMa86NzU) 
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Figure 2.5 Schematic representation of EM algorithm. 
Each black dot and blue dot represent an observation in the dataset. The EM algorithm 
starts with randomly selected parameters (μ1, μ2), and iterates up to points of convergence 
(μc1, μc2). (Figure inspired by Computer Science Department, University of North 
Carolina: https://www.youtube.com/watch?v=XepXtl9YKwc) 
 
In the EM algorithm a set of random initial means are selected (Figure 2.5).  For 
example in a two-dimensional dataset h, assume that the means and covariance of the 
hidden distributions are initially μ1, μ2, 𝜎#&,𝜎##	. Then, the algorithm iterates with the E-
step and the M-step (Equations 2.1 to 2.3). 
E-step:   
The expected value 𝐸)𝑧+,- of each latent variable z is calculated. That is, the probability 
that data point i comes from cluster j has either mean 𝜇&	𝑜𝑟	𝜇#	 using the following 
formula:  
 
 𝐸)𝑧+,- = 𝑃(𝑥 = 𝑥+|𝜇 = 𝜇+, 𝜎2+		)∑ 𝑃(𝑥 = 𝑥+|𝜇 = 𝜇,,𝜎2,	)	9+:&  (2.1) 
 
M-step: 
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A new maximum likelihood hypothesis (ℎ′ = 𝜇′&,	𝜇′#	) is calculated, using computed 
latent variable in E-step (𝐸)𝑧+,-) by the following formula: 
 
𝜇′&	 = ∑ 𝐸)𝑧+,-𝑥+9+:&∑ 𝐸)𝑧+,-9+:&  (2.2) 
𝜎2′&	 = ∑ 𝐸)𝑧+,-(𝑥𝑖−µ𝑗)29+:&∑ 𝐸)𝑧+,-9+:&  (2.3) 
These steps iterate until the difference between two consecutive calculated means 
becomes small in absolute value, which is the point of convergence. The algorithm stops 
and the last two means are the estimated maximum likelihood of parameters (means) by 
which the hidden clusters can be revealed (279, 280). EM is the main element of both 
PPCA and clustering with GMM, which are used in the first study in this thesis (Chapter 
3).  
To determine the number of hidden Gaussian distributions required, the Bayesian 
Information Criterion (BIC) can be applied. BIC is an integrated log likelihood and 
includes a penalty for including too many parameters in the model (Equation 2.4). The 
aim of BIC is to quantify the support for one model over others using odds ratios of 
posteriors of the models that have equal priors5. It compares models with differing 
parameterizations and/or differing numbers of clusters. The larger the value of the BIC is, 
the stronger the evidence for the model and number of clusters (281, 282). 
 
 BIC=-2	*	log	likelihood	(L)	+	p*	log	(N)	 (2.4) 
 
where log likelihood (L) is the maximized log-likelihood of the data given a particular 
model, p is the total number of parameters, and N is sample size. 
2.5.4 Classification 
Classification is a supervised machine learning technique that takes data as input 
and places it into correct categories based on its features (275). For example, 
                                               
5 Prior probability is the probability of an outcome or an event based on the 
current knowledge before an experiment is performed. The prior probability will be 
revised as new data or information become available to produce a more accurate measure 
of the outcome or the event. That revised probability is known as posterior probability. 
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classification could allow the prediction of whether a JIA patient with either blood 
marker A or B will develop persistent or extended oligoarthritis subtypes over time. In 
this example, the blood markers A and B are variables/features and oligoarthritis 
extended or persistent are categories (class/response variable). 
The model first must be trained in order to make precise decisions based on the 
relationship between features (predictor variables) and known class labels (response 
variables). The aim of classification is to predict a response variable based on a set of 
observed predictor variables. It is called supervised machine learning because of the 
training procedure with the known labeled class. There are unsupervised classification 
algorithms in which the response variable is not predetermined. Supervised machine 
learning includes techniques that provide either classification (when the response variable 
is categorical) or regression (when the response variable is continuous) (283).	
2.5.4.1 Classifier 
The classification algorithm is known as a classifier. One of the most popular 
classifiers is decision tree (DT) which can be used for both classification and regression 
purposes. It recursively divides the observations to generate a model that predicts the 
value or class of a variable by learning simple decision rules inferred from input 
variables. A DT consists of internal nodes from which the tree splits into branches, and 
end branches that do not split further (terminal nodes or leaves). The first node is called 
the root node (284). The aim of this classifier is to make a tree with low generalization 
error. The generalization error is the probability of misclassified observations when using 
a trained model in a new set of data. Although it is not possible to calculate the 
generalization error for a future dataset, we can estimate it by calculating the testing set 
error rate of the data to find a desired confidence interval for the generalization error 
(285). 
There are several measures of node impurity, which represents how well the trees 
split the data. The two most common measures of impurity are the Gini impurity criterion 
(Gini index) and an entropy measure. Both are measures of uncertainty or 
misclassification. In other words, they measure how often a randomly chosen observation 
from the set would be misclassified. Gini impurity and entropy are defined as:  
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 𝐺𝑖𝑛𝑖	𝑖𝑚𝑝𝑢𝑟𝑖𝑡𝑦 = 1 −Y𝑝#Z#[Z:&  (2.5) 
 
 
 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = Y𝑝Z[Z:& 𝑙𝑜𝑔#(𝑝Z) (2.6) 
where there are m classes of the response variable indexed by k=1, 2, 3,…, m, and pk is 
the proportion of observations in the mth region that are from the kth class. The measures 
range between 0 and 1. A small value indicates that a node contains observations from a 
single class. In both the Gini index and entropy measure 0 indicates the preferred lower 
error rate. The Gini impurity value is small if all of the pk are close to zero or one, which 
means a node contains predominantly observations from a single class (pure node). In the 
two-class case, the two measures are maximized at pk =0.5 (when observations are 
equally belong to each class) (286). The value of Gini impurity is always between 0 and 1 
regardless of the number of classes; while the value of entropy is larger than 1 if the 
number of classes is more than 2. 
Entropy and Gini impurity can be used to evaluate the quality of a particular split. 
The measure is calculated before and after the split. The impurity value before the split is 
subtracted from those after the split, which are weighted by the proportion of 
observations falling into the classes at each split. The impurity value should be smaller 
after the split than the value before the split. The best and the next split is chosen by 
comparing the reduction in the measures across all possible splits (287). The process 
recursively partitions the remaining training observations until each leaf contains 
observations from one class (288). These two measures are incorporated into the 
classification algorithm that is used in this project (the task of growing a DT). Figure 2.6 
is an example of a DT.  
 A DT produces a model that is easy to understand and can achieve high accuracy, 
but inclines to overfitting (289, 290). Pruning is a method that can handle overfitting. 
After growing the tree to the full depth, the branches that decrease the generalizability of 
the model for future data are removed in succession. The dataset is randomly split into a 
training set and a validation set. The tree is grown on the training portion and then each 
node of the tree is removed successively. The new classifier (pruned tree) is applied to 
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the validation set and its accuracy is evaluated. Based on the accuracy measures of the 
classifier, the algorithm either removes or keeps the node. The process iterates until the 
point that pruning does not make any further improvement in the classifier accuracy 
measures (291). 
 Another drawback of DT is that a small variation in the training set results in a 
completely different tree. Ensemble methods can handle such tree instability issues. The 
methods involve combining several models to improve the accuracy and the individual 
predictions are combined through averaging or voting (289). 
 
 
Figure 2.6 A decision tree.  
 
2.5.4.2 Random forest 
Ensemble learning6  is an approach that trains and combines multiple learners to 
solve the same problem. Ordinary machine learning methods learn one hypothesis from 
training data, while ensemble methods construct a set of hypotheses and combine them. 
Thus, ensemble methods construct a predictive model by integrating multiple models 
(292).  
Random forest, an ensemble learning technique that overcomes the instability problems 
of DT, was first proposed by Breiman (293). The algorithm generates many DTs using a 
                                               
6 A computer program that uses the data to build a DT is called the learner and the 
DT is called the classifier. 
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bootstrap sample of the data (randomly selected subset of observations with 
replacement). For each bootstrap sample, an unpruned classification or regression tree is 
grown (273, 293). At each node, instead of using the best split among the features, a 
subset of variables is selected randomly. 
 The class is assigned by aggregating the predictions of the trees (majority vote in 
classification or averaging in regression problems) (293, 294). Random forest can be 
applied in problems involving more than two classes, can handle noisy variables, and can 
be used when the number of variables is larger than the number of observations. The 
unpruned trees result in low bias, and random variable selection results in low correlation 
among the individual trees (295). 
2.5.4.3 Performance evaluation 
Evaluation of classifiers involves comparing the classification results against 
ground truth or another set of results. In this comparison there are four types of metrics, 
two types of agreement and two types of disagreement. The two forms of agreement are 
called a true positive (TP) and a true negative (TN). A TP result is a state that appears in 
actual and predicted sets (observation that is actually positive and predicted positive). A 
TN result is a state that appears in neither set (observation that is actually negative and 
predicted negative). The two forms of disagreement are false positive (FP) and false 
negative (FN). A FP result is a situation that detects the condition when it is absent. FN, 
opposite of TP,  
does not detect the condition when the condition is present. The FP concept is related to 
type I error and FN is related to type II error used in hypothesis testing. All four types of 
results can be shown in a confusion matrix (Table 2.3).  
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Table 2.3 The confusion matrix for comparing two sets of conditions. 
 
 
Classifier performance evaluations consist of: 
 
 Sensitivity	(recall)= TPTP+FN	 (2.7) 
Sensitivity measures the proportion of positive observations that are correctly classified. 
  
 Specificity= TNTN+FP	 (2.8) 
   
Specificity measures the proportion of negative observations that are correctly classified. 
 
 Precision	(PPV)= TPTP+FP	 (2.9) 
Precision or positive predictive value (PPV) is the proportion of observations identified 
as positive and are truly positive. 
 
 Negative	predictive	value	(NPV)= TNTN+FN	 (2.10) 
Negative predictive value (NPV) is the proportion of observations that identify as 
negative and are truly negative. 
 
 Accuracy= TP+TNTP+TN+FP+FN	 (2.11) 
Accuracy represents the proportion of observations classified correctly. 
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 F-measure=2 × precision×recallprecision	+	recall	 (2.12) 
F-measure is harmonic mean of the precision (PPV) and recall. It is a measure to see the 
balance between precision and recall when there is an uneven class distribution (296). 
There is a trade-off between FN and FP outcomes. Being more stringent typically 
results in fewer FPs and more FNs. The opposite is true when one is less stringent. The 
classifier accuracy measures capture this trade-off, which can be characterized by the 
receiver operating characteristic (ROC) curve (Figure 2.7). ROC graph is a two-
dimensional graph plotting the sensitivity on the y-axis versus (1 – specificity) on the x-
axis. The graph shows the cut-off points between benefits (TP) and costs (FP) and the 
ability of a binary classifier to rank the positive observations against the negative 
observations. The diagonal line on the graph represents guessing a class randomly. The 
point (0.5, 0.5) in ROC space shows when a classifier randomly predicts the positive 
class half of the time. It can be expected to get 50% of the positives and 50% of the 
negatives correct (i.e., no better than random guessing; see Figure 2.7, line C). Any 
classifier that appears in the upper left triangle performs better than random guessing and 
any classifier situated in the lower right triangle performs worse than random guessing. 
Between two models (for example, A and B in Figure 2.7) that test the same hypothesis, 
the model with the higher area under its ROC curve is considered the better one (Figure 
2.7 comparing the ROC curves of Model A and Model B). A perfect classifier would 
have an AUC of 1 while random guessing would result in an AUC of 0.5 (297, 298).  
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Figure 2.7 ROC curve.  
An example of two ROC curves (A and B), and the performance level that could be 
expected from random guessing (C). In this case, model A is more accurate than B. 
 
In summary, data reduction methods help to transform a large dataset into a small 
set that is more understandable numerically and visually. Before applying clustering and 
classification algorithms, the data used in this research was reduced into new sets of 
variables in the first study (JIA clustering), and for the second study (predicting 
outcomes), variable selection methods were used. For study 1, clusters should be 
identified as much as possible by patients’ information but in a consice form. For study 2, 
the idea was to identify a limited number of reliable predictors of disese activity, 
especialy if they could predict outcomes of all JIA categories. For that reason, feature 
selection methods were applied in the second study. In study 1, data-driven unsupervised 
machine learning clustering algorithms were used to reveal hidden patterns that enable 
categorization of disease based on clinical and biological attributes. Supervised machine 
learning algorithms help overcome limitations of conventional statistical models and find 
reliable predictors in a relatively small panel of clinical measures and inflammation-
related biomarkers. Because class variables were binomial, classification was used for 
study 2.  
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CHAPTER 3 
STUDY 1. CLINICAL AND BIOLOGICAL FEATURES FOR CLUSTERING WITHIN A COHORT 
OF CHILDREN WITH CHRONIC ARTHRITIS 
3.1 Abstract 
  Objective: To identify discrete clusters comprising clinical features and 
inflammatory biomarkers in children with JIA and to determine cluster alignments with 
JIA categories.  
Methods: A Canadian prospective inception cohort comprising 150 children with 
JIA was evaluated at baseline (visit 1) and after six months (visit 2). Data included 
clinical manifestations and inflammation-related biomarkers. PPCA identified sets of 
composite variables or PCs, from 191 original variables. To discern New Clinical-
Biomarker Clusters (Clusters), GMM were fit to the data. Newly-defined Clusters and 
JIA categories were compared. Agreement between the two was assessed using Kruskal-
Wallis tests and heat map plots. 
Results: Three PCs recovered 35% (three Clusters) and 40% (five Clusters) of the 
variance in patient profiles in visits 1 and 2, respectively. None of the Clusters aligned 
precisely with any of the seven JIA categories, but rather spanned multiple categories. 
Results demonstrated that the newly defined Clinical-Biomarker Clusters are more 
homogeneous than JIA categories.  
Conclusion: Applying unsupervised data mining to clinical and inflammatory 
biomarker data discerns discrete Clusters that intersect multiple JIA categories. Results 
suggest that certain groups of patients within different JIA categories are more aligned 
pathobiologically than their separate clinical categorizations suggest. Applying machine 
learning analyses to complex datasets can generate insights into JIA pathogenesis and 
should contribute to biologically-based refinements in JIA classification. 
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3.2 Background 
JIA is a heterogeneous group of diseases categorized predominantly according to 
clinical manifestations by ILAR (299, 300). 
Only two biomarkers, RF and HLA-B27, are considered when classifying JIA (2). 
Ravelli et al. showed that ANA-positive patients belonging to oligoarticular or 
polyarticular JIA categories share the same characteristics, suggesting that they represent 
the same disease (301, 302). However, considering a broader panel of clinical and 
biologic features was shown to generate childhood arthritis subsets distinguishable from 
conventional JIA categories (39).  
By applying unsupervised data mining algorithms, this present study aimed to 
identify discrete clusters of patients comprising clinical and inflammatory biomarker 
attributes and ascertain the extent to which these patient clusters align with currently 
defined JIA categories. This study extends earlier observations as it assesses a broader 
array of inflammatory biomarkers and determines changes in cluster composition over 
time. Applying machine learning analytical frameworks to large clinical and biologic 
datasets can contribute new insights into JIA pathogenesis and should help inform a 
future biologically-based JIA classification. 
3.3 Methods and data collection 
Data were from a Canadian prospective longitudinal inception cohort, The BBOP 
Study, comprising children with new-onset JIA enrolled consecutively within six weeks 
of first presentation at a participating pediatric rheumatology centre (N=11 participating 
sites). Ethics review boards from all sites approved the study (Appendix, supplementary 
text 1and 2) and informed consent/assent was obtained. The recruitment strategy aimed 
for a reasonable number of participants in each of the seven JIA categories rather than 
aspiring to achieve a typical JIA subgroup distribution. To achieve this aim, only 
participants with polyarthritis or systemic JIA were eligible during the first six months of 
the enrollment period; after six months and until the end of the two-year enrollment 
period participants with any JIA category were eligible. Demographic, clinical, functional 
ability (CHAQ) (239), quality of life (JAQQ) (31) and laboratory data were collected at 
enrolment and six months later (visits 1 and 2). 
Blood was collected in P100 tubes (BD Biosciences) (39, 303) at both visits and 
plasma stored at -80°C. Biomarkers were assayed by bead-based multiplex or individual 
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enzyme immunoassays as detailed in Appendix A, supplementary text 2. The biomarker 
panel was selected to broadly represent Th1 and Th2 pro- and anti-inflammatory 
cytokines, growth factors, chemokines, and extra-cellular matrix and bone degradation 
markers. High mobility box 1 protein (HMGB1) and soluble low-density lipoprotein 
receptor-related protein 1 (sLRP1) were tested as upstream mediators of inflammatory 
pathways (304-307). Test results for ANA by indirect immunofluorescence assays, RF, 
and HLA-B27 were from clinical laboratory testing facilities affiliated with each study 
site and results dichotomized as positive or negative. The biomarkers assayed are listed in 
Table 3.1. 
 
Table 3.1 Plasma biomarkers measured at enrolment and 6 months after. 
 
MMP, matrix metalloproteinases; TIMP, tissue inhibitor of metalloproteinase; IL, 
interleukins; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor 
kappa-Β ligand; RANTES, regulated on activation normal T cell expressed and 
secreted; IP-10, interferon gamma-induced protein 10; MCP-1, monocyte 
chemoattractant protein; MIP, macrophage inflammatory proteins; G-CSF, 
granulocyte-colony stimulating factor; GM-CSF, granulocyte macrophage colony-
stimulating factor; VEGF, vascular endothelial growth factor; EGF, epidermal 
growth factor; FGF-2, Fibroblast growth factor; INF, interferons; TNF, tumor 
necrosis factor; HMGB1, high mobility group box; sLRP-1, soluble low-density 
lipoprotein receptor-related protein. 
3.4 Data analysis 
Software and data pre-processing: Statistical analyses were performed using 
SPSS Statistics Professional, version 23, and R, version 3.2.2. Circos, version 0.63, was 
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used for generating contingency wheels to depict relationships between New Clinical-
Biological Clusters (Clusters) and JIA categories (308). Extreme values were removed 
using outlier-labeling (309). Data had 20% missing values were imputed using multiple 
imputation regression (310). Protein concentrations and continuous variables were log- 
and Z -score- transformed.  
Variable selection and dimensionality reduction: PPCA reduced the 
dimensionality of the dataset from 191 variables, consisting of clinical and biomarker 
measurements, to a reduced number of PCs (255, 262, 280, 311).  
 
 
Figure 3.1 Q2 plots for both visits. 
They identify the number of principal components in visit 1 (left) and visit 2 (right). Q2 is 
the goodness measure of prediction (defining the average error of prediction) used for 
internal cross-validation, which allows the identification of the optimal number of PCA 
loadings. 
 
The number of PCs retained from PPCA was selected by maximizing the Q2 
metric, which reflects how well the original dataset could be reconstructed from the 
retained PCs. Q2 was calculated using 10-fold cross-validation and plotted against the 
number of PCs (Figure 3.1) (312, 313). 
 To facilitate interpretation and increase the stability of each retained PC, we 
performed leave-one-variable-out cross-validation with PPCA and if at least 5% of the 
runs resulted in a contribution (variable contribution -in percentage- involves squaring the 
variables’ loading) less than 2% then the variable was eliminated. In the end, 37 and 38 
variables were retained in three PCs in visit 1 and three PCs in visit 2, respectively. 
Clustering: To identify Clusters of patients using the PCs, GMMs were applied as 
provided by the R package mclust (v5.0). Mclust software fits various GMMs (280), 
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which assume data arise from multiple Gaussian distributions, and uses BIC to select the 
model with the optimal number of Gaussian kernels and shape constraints (314). 
Stability: Homogeneity of Clusters was compared to JIA categories using 
Kruskal-Wallis test p-values (ranging from 10-9 to 10-1) (315). The proportion of 
variables with p-values less than each threshold was graphed separately for Clusters, JIA 
categories, clinical variables, and biological variables. 
For sensitivity analysis, LOO-CV was performed to assess robustness of Clusters 
to choices of both variables and patients (252, 316). In the first LOO-CV analysis, each 
variable was removed sequentially, and the entire analysis was repeated to produce 
Clusters comprising all but the excluded variable. The second analysis (sensitivity toward 
patients) was conducted in a similar manner, except that instead of removing variables, 
10% randomly selected patients were removed at a time. 
3.5 Results  
The distributions of JIA categories and demographic characteristics of the 150 
patients are shown in Table 3. 2. 
 
Table 3.2 JIA category and demographic characteristics represented in the study cohort.  
 
IQR, interquartile range; ERA, enthesitis related arthritis 
Three indicators produced by principal components: For visit 1, 3 PCs (PC-1a, 
PC-1b, and PC-1c) effectively represented the original dataset as reflected by the Q2 
score; for visit 2, the Q2 score was highest when 2 PCs were chosen, but to be consistent 
with the first visit, three PCs (PC-2a, PC-2b, and PC-2c) were also retained for visit 2. 
The three PCs recovered 35% and 40% of the variance from patient profiles in visit 1 and 
2, respectively. 
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As depicted in Figure 3.2, in visit 1, PC-1a comprised only inflammation-related 
cytokines and growth factors. PC-1b was defined by the number of active and effused 
joints, PGA, CHAQ scores, levels of CRP, RF positivity, MMPs, TIMPs, and MIP-1α. 
PC-1c comprised fever, onset age, systemic onset JIA rash, erythrocyte sedimentation 
rate (ESR), CRP, hemoglobin level, white blood cell (WBC) count, and levels of TIMP-
1, epidermal growth factor (EGF), and vitamin D. 
 
Figure 3.2 Variables contribution. 
Normalized principal component (PC) loadings of variables. Variables and the strength of 
their respective contributions to each of the PCs at visits 1 (left) and 2 (right) are shown. 
The darker the color, the stronger the contribution that variable makes to the PC.  
 
As shown in Figure 3.2, in visit 2, PC-2a comprised inflammation-related 
cytokines, growth factors, and MMPs.  
PC-2b was defined by clinical manifestations including onset age, serositis, 
hepatosplenomegaly and enthesitis, levels of MMPs and TIMP-4, inflammatory 
cytokines, and bone degradation biomarkers. PC-2c comprised the number of active and 
effused joints, PGA and JAQQ scores, RF positivity, and laboratory measures of disease 
activity including hemoglobin, platelet count, ESR, CRP, and vascular endothelial growth 
factor (VEGF). 
Three and five Clusters of patients recovered by GMMs: On the basis of the BIC 
(visit 1 model EVI with BIC=-1710.7 and visit 2 model EEE with BIC=-1698.3), three 
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and five patient clusters were retained in visit 1 and 2 respectively (Figure 3.3) and 
designated as V1.1 to V1.3 and V2.1 to V2.5. 
 
Figure 3.3 The mclust options to select Cluster number and shape.  
Bayesian information criterion (BIC) identified three Clusters in visit 1 and five Clusters 
in visit 2; in visit 1 the model VEI and in visit 2 the model VVI had the highest BICs 
respectively. Constraints imposed on Clusters by different criteria: EII, spherical, equal 
volume; VII, spherical, unequal volume; EEI, diagonal, equal volume and shape; VEI, 
diagonal, varying volume, equal shape; EVI, diagonal, equal volume, varying shape; 
VVI, diagonal, varying volume and shape; EEE, ellipsoidal, equal volume, shape, and 
orientation; EVE, ellipsoidal, equal volume and orientation; VEE, ellipsoidal, equal shape 
and orientation; VVE, ellipsoidal, equal orientation; EEV, ellipsoidal, equal volume and 
equal shape; VEV, ellipsoidal, equal shape; EVV, ellipsoidal, equal volume; VVV, 
ellipsoidal, varying volume, shape and orientation; *, indicator of the chosen model. 
 
Visit 1 (Table 3.3): In visit 1, V1.1, the largest Cluster (87 patients) comprised 55 
females (63.2%), older children (mean first presentation age, 10.0±4.5 years) and was 
characterized by having the fewest number of active joints compared to other V1 Clusters 
(four on average with knees most frequently involved); intermediate levels of laboratory 
indicators of disease activity (LIDA), including WBC count, platelet count, ESR, and 
CRP; and low levels of inflammatory cytokines. ANA and HLA-B27 positivity were both 
most frequent in V1.1.  
V1.2 was an intermediate-sized Cluster (45 patients) comprising 33 (73.3%) 
females and with patients having an average age of 9.6 + 5.2 years. This group had the 
highest number of active joints (14) with wrists predominantly involved, the highest 
LIDA, and intermediate levels of inflammatory cytokines.  
The smallest Cluster in visit 1, V1.3, comprised 18 patients, all female, with a 
mean age of 7.2 + 4.6 years. Patients in this group had an average of six active joints, 
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predominantly knees, and intermediate levels of LIDAs. This group had the highest levels 
of inflammatory related cytokines, chemokines, and growth factors and the highest levels 
of sLRP1, HMGB1 and vitamin D. Appendix A, Table A.1 shows biomarker ranks for 
each cluster at visit 1. 
Visit 2 (Table 3.3): In visit 2, V2.1 was the largest of the five Clusters (45 
patients) and included 35 (77.8%) females; patients had a mean age of 11 + 4.5 years, and 
an average of five joints involved, predominantly ankles. This group was characterized 
by intermediate LIDAs and low levels of plasma cytokines except for OPG.  
V2.2 comprised 27 patients of whom 17 (63.0%) were female. Mean age was 10 
+ 4.7 years. An average of two joints were involved, predominantly knees. The group 
was characterized by intermediate levels of inflammatory cytokines/chemokines with 
predominance of IL IL-1b, IL-8, IL-6, MCP-1, and MIP-1a.  
V2.3 with 13 patients comprised 10 (76.9%) females and had an average age 7.0+ 
5.2 years, an average joint count of six active joints (predominantly ankles), and high 
LIDAs. Patients had high levels of sLRP1 and HMBG1 and the highest proportion of RF 
positivity.  
V2.4, with 29 patients, included 24 (82.8%) females. The group had an average 
age of 9+4.8 years and on average two active joints (predominantly wrist). This group 
had the highest LIDAs and inflammatory related cytokine levels, and high sLRP1 and 
HMBG1.  
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Table 3.3 Cluster characteristics in visits 1 and 2.  
ANA, RF, and HLA-B27 are not included in the table due to amount of missing data in 
visit 2.  
 
NSAID, non-steroidal anti-inflammatory; DMARD, disease modifying anti-
rheumatic drug; Biologic, biologically-based therapies; IQR, interquartile range. 
 
V2.5, with 36 patients, was the second-largest Cluster in visit 2. The group 
included 31 (86.1%) females, had an average age of 10 + 4.1 years, the lowest number of 
active joints (one on average) with a high rate of knee involvement. The group had low 
inflammation-related cytokine levels and had the highest frequency of ANA-positivity.  
Appendix A, Table A.2 lists biomarker ranks for each Cluster at visit 2.  
Clinically meaningful patterns: Clusters were compared to JIA categories using, 
chi-square test, Circos (Figure 3.4), and the Kruskal-Wallis test (Figure 3.6). The 
analyses demonstrated that the Clusters did not align consistently with JIA categories 
(chi-square p<0.001) and that PC scores of patients in each Cluster were more 
homogenous than in each JIA category, especially for the first PC, which represents 
inflammatory biomarkers.  
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Figure 3.4 Contingency wheel plots comparing JIA and Clusters. 
The contingency wheel plots depict the relationships between Clusters (right semicircle) 
and JIA categories (left semicircle) at visit 1 (left circle) and visit 2 (right circle). 
Individual patient scores for each of the three principal components (PCs) are depicted as 
stacks of three rectangles in the three outermost layers of the wheel (labeled as PC 1/2 a, 
b, c). The color scale in each of the three rectangles comprising the stacks from each 
individual patient indicates the magnitude of patient scores for each PC in accord with the 
gradient color scale legend. Each Cluster and each JIA category, shown in layer a, is 
distinguished by a different color. The right-hand side of the innermost layer (b) of each 
Circos figure illustrates the alignment of each individual patient (represented by the 
patient’s JIA category color) within the respective Clusters. Similarly, the left side of 
each Circos figure illustrates the alignment of each individual patient (represented by the 
Cluster color) within the respective ILAR-defined JIA categories. Colored ribbons link 
clusters and JIA subtypes. Numbers of patients are proportional to the width of the 
ribbons; thus, thicker ribbons depict that more patients are shared between newly defined 
Clusters and JIA category. 
 
In visit 1 (Table 3.3), patients in four of the seven JIA were predominantly 
assigned to V1.1; specifically, all seven of those in the undifferentiated category (100%), 
10 of 1l (90.9%) in the psoriatic arthritis group, 9 of 11 (81.8%) in the ERA group and 30 
of 42 (71.4%) in the oligoarticular group aligned with V1.1. The majority of patients with 
oligoarthritis (30 of 42 patients; 71.4%) and nearly half of those with RF-negative 
polyarthritis (24 of 50 patients; 48%) were assigned to the V1.1. Five of the seven JIA 
categories had some patients with strong associations with variables in PC-1a and PC-1b, 
PCs comprising predominantly inflammatory cytokines and MMPs/TIMPS; in contrast, 
all patients with strong PC-1a and PC-1b associations clustered in one group (V1.3) in the 
new clustering scheme. 
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Table 3.4 Percentages of patients in each JIA category and their distribution into Clusters 
in visit 1 and 2. 
 
Large subsets of patients with RF-negative polyarthritis grouped to V2.1 (Table 
3.3). Few patients with psoriatic arthritis, ERA, and undifferentiated arthritis had high 
levels of inflammatory cytokines after six months; they grouped into either V2.3 or V2.4. 
Figure 3.5 shows how visit 1 clusters split to constitute visit 2 clusters. Next, we assessed 
homogeneity of Clusters relative to JIA category using chi-square (p<0.001) and Kruskal-
Wallis tests (Figure 3.6). Relative to JIA category, both visit 1 Clusters and Visit 2 
Clusters had a higher proportion of variables that were statistically significant at any p-
value threshold (Figure 3.6, upper graph). When considering only clinical variables, visit 
2 clusters had the highest proportion followed by JIA category and visit 1 Clusters 
(Figure 3.6, middle graph). Lastly, when considering biologic variables only, both 
clusters had a markedly larger proportion of statistically significant variables at any p-
value threshold relative to JIA category (Figure 3.6, lower graph). 
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Figure 3.5 Contingency wheel comparing visit 1 and visit 2. 
The contingency plot depicts the relationship between Clusters at enrollment (visit 1) and 
Clusters at six months after enrollment (visit 2). See Figure 3.4 for description of wheel 
elements. 
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Figure 3.6 Kruskal-Wallis p-values. 
Proportion of Kruskal-Wallis p-values ≤ 0.05 for Clusters in visit 1 and 2 tended to be 
higher than for the JIA categories when considering all variables (upper graph) and 
biological data (lower graph). JIA categories have a higher proportion of Kruskal-Wallis 
p-values ≤ 0.05 compared to the visit 1 Clusters and lower values than the visit 2 while 
considering only clinical variables (middle graph). 
 
These results demonstrate that Clusters are more homogeneous than JIA 
categories and that homogeneity improves from visit 1 to visit 2 (which might be in part 
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due to treatment response). For example, profiles characterized by intermediate levels of 
cytokines (Figure 3.5) were almost exclusively aligned with V2.4, a Cluster containing 
patients from all seven JIA categories. This suggests that, with respect to inflammatory 
cytokines, subsets of patients from different JIA categories are more concordant than 
their distinctive JIA categorizations might imply. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Variable sensitivity analysis. 
Leave-One-Variable-Out Cross-Validation (LOVO-CV), visit 1 (upper) and visit 2 
(lower). By removing one variable at a time and measuring the co-clustering probability, 
the Clusters remain the same with median of 93% in visit 1 and 89% in visit 2. 
 
Sensitivity analysis determined how robust clustering was to removal of different 
variables and patients. In variable sensitivity analysis, the entire analysis was repeated 37 
times for visit 1 and 38 times for visit 2, each time holding back one variable. Then co-
clustering probabilities were computed. Results indicate that in visit 1, 70%-100% 
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(median=93%) and in visit 2, 69%-100% (median=89%) of the time patients remained in 
the same Clusters (Figure 3.7). 
Sensitivity analysis for patients showed that visit 1 and visit 2 were approximately 
equally sensitive to removal of 10% of patients; in visit 1, 73%-94% (median=84%) and 
in visit 2, 74%-92% (median=86%) of the time patients remained in the same Clusters 
(Figure 3.8). 
 
Figure 3.8 Subject sensitivity analysis. 
Boxes show the co-clustering probability (calculated using 100 iterations) after removal 
of 10% of subjects at visit 1 (left) and visit 2 (right). In visit 1, patients remain co-
clustered with median of 84%, and in visit 2, with median of 86%. 
 
3.6 Discussion 
Using data-driven, machine learning analytical approaches in a JIA cohort, 
discrete Clusters arise comprising clinical and inflammatory biomarker attributes that 
tend to intersect multiple JIA categories and that change from the time of diagnosis to 6 
months later. Our results suggest that certain pathobiologic processes are shared among 
JIA categories and fluctuate during the course of the disease. 
PC-1a of visit 1, comprised mostly pro-inflammatory cytokines (ILs, IFNs, GM-
CSF, and TNF-β), demonstrating the role of inflammatory cytokines in the 
pathophysiology of chronic childhood arthritis early in the disease. Anti-inflammatory 
cytokines including IL-10, IL-2, and IL-4 were also expressed in PC-1a. PC-1b 
constituted clinical features including number of joints with active arthritis and 
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parent/patient/physician assessment of overall well-being and functional ability. In 
addition, PC-1b identified significant correlations among MMP-1, -8, and -9, TIMP-4, 
and MIP-1a. Our findings and previous reports of expression of MMP-1 and -3, and 
TIMP-1 in JIA synovial fluid and correlation with disease activity (218, 317) suggests 
that type II collagen degradation, mediated partly by MMP-1 and -3, can begin early in 
some patients and might portend a poorer prognosis (218). PC-1c was characterized by 
fever, systemic rash, low hemoglobin and elevated acute phase reactants, all features of 
systemic JIA (318). 
In visit 2, plasma inflammatory cytokine levels were retained in PC-2a, although 
their contribution was weaker than in visit 1 (Figure 3.2). PC-2b showed associations of 
both systemic JIA and ERA features with IL-7 and TNF-α. IL-7 promotes Th1 and Th17 
activation and production of pro-inflammatory mediators MIP-1, MIP-3, MCP-5, and 
TNF-a (319-321) in addition to promoting osteoclastogenesis by up-regulating RANKL 
(322, 323). Although systemic JIA and ERA are clinically distinguishable, bone 
degradation seen in some patients with systemic JIA and in some with ERA could be 
mediated by common osteoclastogenic pathways in both conditions. PC-2c grouped 
clinical measures of disease activity including numbers of active and effused joints and 
parent/patient/physician assessments of overall well-being and functional ability. 
When considering inflammatory biomarkers along with clinical features, Cluster 
assignments are dynamic; patients aligned with one of three Clusters at enrollment but to 
one of five Clusters six months later, reflecting alterations of clinical and inflammatory 
processes over time. These temporal changes could be a consequence of treatment 
interventions and/or inherent modulations of inflammatory processes.  
In visit 1, 100%, 78%, and 42% of ANA-positive patients with psoriatic arthritis, 
oligoarthritis, and RF-negative polyarthritis, respectively, were retained in Cluster-
1(V1.1). Ravelli et al. suggested that some patients with similar characteristics can be 
assigned to different JIA categories (324). For example, ANA-positive female patients 
classified as oligoarthritis, RF-negative polyarthritis, and psoriatic arthritis are more 
similar than their different designations might suggest (51, 324). Our findings tend to 
support this idea although ANA was not a determinant variable in our models (324).  
In this study, variable and subject sensitivity analysis indicated that Clusters 
described are robust to small variations in data. In visit 1, removal of any of 15 of 37 
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variables resulted in insignificant disruption of clustering. Our results are in accord with 
those of Eng et al. in a study that considered a smaller subset (n=102 compared to our 
with n=150) of the enrolment BBOP cohort and a smaller number of biomarkers (18 
compared to our 48) (39). 
Sensitivity analysis shows that the Clusters are robust and unaffected by data 
perturbation. Nine biological variables (INF-γ, IL-12p70, IL-15, IL-1Rα, IL-1α, IL-2, IL-
4, TNF-β, and VEGF) in visit 1, and one (IL-17) in visit 2 had co-clustering probability 
equal to 1, which indicates that removal of each of them individually cannot affect the 
clustering scheme. The IL-2/IL-21 gene locus 4q27 is associated with susceptibility to 
JIA (325). Variant loci of IL-2, IL-2RA, and IL-2RB are associated with oligoarticular 
and RF-negative polyarticular JIA (325, 326). The role of IL-2 in defining disease groups 
by sensitivity analysis at visit 2 supports a role for IL-2 in the immunopathogenesis of 
JIA. 
This study did not include other biomarkers relevant to JIA, such as S100 and 
serum amyloid A (180), genomic markers (broad HLA typing, genetic polymorphisms), 
gene expression, or metabolomics profiling. Applying the same machine learning 
analytical frameworks to a broader array of clinical and biologic features should help 
further elucidate underlying pathogenic processes and might aid in refining disease 
classification.  
We did not investigate reasons for changing profiles over time. Future studies are 
required to ascertain how treatments influence clinical-biomarker profiles. Panels 
comprising a small number of clinical-biomarker attributes could then be applied to 
predict and detect treatment responsiveness and provide more conceived rational, 
biologically-directed personalized treatment at a lower cost.  
Biomarker levels can be influenced by diurnal variations and physical activity 
(327), variables not controlled for in this research. Further, in addition to our sensitivity 
analyses and cross-validation, generalizability of the reported PCs requires validation in 
an independent cohort.  
3.7 Conclusion 
In JIA, data-driven machine learning algorithms uncover distinctive Clusters 
comprising clinical and biomarker attributes. Considering biomarker profiles with clinical 
characteristics can contribute to understanding JIA pathogenesis and may lead to refining 
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subgroup classifications. We anticipate that this type of data-driven classification of 
patients will ultimately allow for a more precise personalized approach to diagnosis, 
prognostication,and treatment of children with JIA.  
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CHAPTER 4 
STUDY 2. BIOLOGICAL AND CLINICAL PREDICTORS OF SHORT-TERM OUTCOMES OF JIA 
4.1 Abstract 
Objective: The objective of this study was to identify early predictors of short-
term arthritis activity in JIA using clinical and biomarker profiling. 
Methods: Clinical and inflammatory biomarker data were collected in a 
prospective longitudinal cohort of 96 newly-diagnosed children with JIA. Presence or 
absence of active joints, PGA, and Wallace criteria were chosen as outcome variables 18 
months post-enrolment. Correlation-based feature (variable) selection and ReliefF were 
used for feature selection. A random forest was trained to predict outcomes based on the 
selected features. 
Results: From the original 112 features, 17 effectively predicted outcome after 18 
months. The variables included onset age, wrist/foot involvement, number of active and 
effused joints, systemic JIA rash, white blood cell count, erythrocyte sedimentation rate, 
platelet counts, and plasma levels of eight inflammatory biomarkers (IL-1α, IL-10, IL-15, 
IL-17, IL-12p70, TIMP-4, GM-CSF, and VEGF). The panel predicted presence or 
absence of active arthritis, physician global assessment, and Wallace criteria of inactive 
disease after 18 months with 79%, 82%, and 71% accuracy and 0.83, 0.86, 0.82 AUC, 
respectively. The accuracy and AUC values were higher compared to when only clinical 
features were used for prediction.  
Conclusion: This study showed that a small number of clinical and inflammatory 
features at diagnosis can more accurately predict short-term arthritis activity in JIA than 
clinical characteristics only. Considering clinical features together with a broader array of 
biomarkers should yield more refined prediction of future arthritis activity and guide 
more rationally-conceived, biologically-based early JIA treatment strategies.  
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4.2 Background 
JIA encompasses a heterogeneous group of diseases categorized predominantly by 
clinical manifestations including the number of affected joints and the presence of certain 
extra-articular features (328). Only two biological variables, RF and HLA-B27 are 
considered in the JIA classification system. The intent of the JIA taxonomy is to assign 
patients, for research purposes, with similar characteristics at onset to categories 
presumed to share similar pathophysiology, treatment responses, and outcomes. 
However, even within the same JIA category patients exhibit different disease courses 
and outcomes. Thus, JIA category assignment alone does not always reliably predict 
which children are destined for a favourable or unfavourable outcome (61, 62).  
In general, studies in the era of biologically-based pharmacotherapies indicate 
improving outcomes (329). Nearly half of children with JIA are estimated to have 
inactive disease within a year after diagnosis when biologics are used sparingly (330). 
More generous use of biologics results in up to 80% of JIA patients having inactive 
disease (331, 332). However, recommending a biologic in a child with JIA requires 
judicious assessment of baseline disease characteristics and severity and an informed 
expectation that outcomes will improve with the chosen therapy. Previous studies have 
identified predominantly clinical predictors of poor prognosis (30, 37, 68, 71). Improving 
the effectiveness with which JIA outcomes can be predicted early in the disease course by 
encompassing clinical characteristics with biomarker profiling could further refine patient 
selection for early aggressive treatment. There are limited studies that have evaluated the 
utility of a broad array of inflammatory biomarkers together with clinical characteristics 
for predicting JIA outcomes (333, 334). Our objective was to identify, in a JIA inception 
cohort, panels of clinical and biomarker attributes that could predict short-term disease 
activity as reflected by presence of active arthritis, PGA, and Wallace criteria (29).  
4.3 Methods and materials 
Data collection: Data were from The BBOP Study. Ethics review boards at the 11 
participating sites approved the study. BBOP data included 282 clinical characteristics 
and 48 plasma inflammatory biomarkers. Study participants were diagnosed according to 
ILAR classification (328). Prior to enrollment, subjects had not received systemic 
therapies beyond non-steroidal anti-inflammatory medications and/or methotrexate. From 
the entire BBOP cohort of 186 participants 96 were selected for the current study based 
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on availability of complete outcome data at the 18-month follow-up visit. Demographic 
(Table 4.1), clinical, and laboratory data were collected prospectively at enrolment (visit 
1) and 18 months later (visit 2). Pediatric rheumatologists conducted a joint examination 
at each assessment and documented the number of active joints and number of effused 
joints. The pediatric rheumatologist also completed a physician global assessment of 
disease activity using a horizontal 10 cm visual analogue scale from 0=no disease activity 
to 10=maximum disease activity. 
In accord with previously described standardized protocols peripheral blood was 
collected in P100 tubes (BD Biosciences) and plasma stored at -80°C until assayed (303). 
The list of biomarkers included in the panel is shown in Table 3.1. 
Table 4.1 Patient’s characteristics at the first visit. 
 
    M, male; F, female; IQR, interquartile range; SD, standard deviation; outcome 1, active   
joint; outcome 2, PGA; outcome 3, Wallace criteria. 
 
Biomarkers assayed are described in supplementary text 2. ANA test results were 
from indirect immunofluorescence assays performed at clinical laboratory facilities at 
each study site and results dichotomized as positive or negative; ANA patterns and titers 
were not recorded. 
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4.4 Outcome indicators  
Three independent outcome measures were considered to define inactive and 
active disease 18 months after diagnosis. The first outcome indicator was based on the 
presence or absence of active arthritis (n=88), with active arthritis defined as the presence 
of intra-articular swelling and/or limitation of joint motion with one or more of the 
following: swelling, warmth, pain on motion, tenderness. The second indicator was based 
on PGA score (n=93), with active disease defined as PGA>1cm and inactive disease 
defined as PGA<1 cm. The third was based on Wallace criteria of active/inactive disease 
(n=54) (29).   
4.5 Feature selection  
FS can be applied to a large dataset to select the optimal features for class 
prediction and it is valuable for analyzing high-dimensional data (that is, datasets in 
which the number of features exceeds the number of subjects) (268). By eliminating 
redundant and irrelevant features, FS techniques improve prediction accuracy. FS aims to 
project the original data, which has a large number of features, onto a smaller number of 
features while preserving the most important information. In this study, we used two 
filter-based FS approaches: CFS and ReliefF (335). In filter methods, features are 
selected on the basis of their scores in various statistical tests by looking at the properties 
of the data (336). CFS and ReliefF are multivariate methods that consider relationships 
among the features. CFS is based on the rationale “a good feature subset is one that 
contains features highly correlated with the class, yet uncorrelated with each other” 
(272). It assesses both redundancy of features by applying correlation algorithms and the 
predictive ability of a subset of features (273). ReliefF chooses the features that are 
distinct among different classes (337). The basic idea of ReliefF is to select subjects 
randomly, compute their nearest neighbors (nearest subjects), and to identify features that 
discriminate the subject from neighbors of different classes. Specifically, ReliefF 
randomly draws a subject (A) and then identifies its two nearest neighbors: one from the 
same class (nearest hit, H) and the other from the different class (nearest miss, M). It then 
calculates differences between features from subjects A and H and between A and M. A 
desirable scenario is when the subjects A and M have different values of a particular 
feature and that feature discriminates two subjects with different class values. If subjects 
   
 
70 
A and H have similar values of the individual feature, then that feature does not separate 
two subjects with the same class values. 
To estimate a weight for each feature (f), the algorithm uses the following 
probability equation:  
 
 
The operation is iterative and gives more weight to the features that discriminate the 
subject from the neighbors of a different class (338). High-ranked features identified by 
both CFS and ReliefF were selected for further analysis. 
4.6 Predicting outcome in JIA based on clinical and biological features 
To determine how well a constellation of selected features predicts JIA outcome, 
the random forest classification algorithm was applied (339). In the dataset used to derive 
the random forest algorithm, each patient represented a subject. A prediction model was 
trained using 90% of the data (training set) randomly, and then the model was tested on 
the remaining 10% of the data (test set). This procedure is iterative and is called10-fold 
cross-validation. The ultimate goal of the random forest classification algorithm was to 
maximize the predictive accuracy of the trained model on the new data (290). 
The random forest algorithm generates many decision trees (each of which 
predicts the class value by learning simple decision rules inferred from the selected 
features) from randomly selected subsets of the subjects and features (339). There are two 
assumptions: first, most of the trees correctly predict the class for most of the subjects, 
and second, the trees make mistakes at different places. According to these assumptions, 
the algorithm conducts voting for each of the classes and collectively ranks the 
importance of features in predicting the correct class (294, 339).  
By default, Weka (data mining software) injected randomness into the training 
procedure by randomly selecting log2 (number-of-features+1) subjects from the dataset 
prior to training each decision tree. 
The mean decrease in accuracy of a feature was determined during the cross-
validation. A single feature was excluded from the test set then accuracy rate of the 
Weight (f)=  
P(different value of (f)|different class)−P(different value of (f)|same class)                (4.1) 
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model was calculated. The feature was considered more important if its removal caused a 
large decrease in the model accuracy measurements.  
4.7 Data analysis  
Statistical analyses were performed using SPSS Statistics Professional v23, and R 
v3.2.2. Weka was used for feature selection and prediction (340). The outlier-labeling 
rule was applied to identify and remove extreme values (309). Protein concentrations and 
continuous features were log and Z-score transformed.  
For each outcome, ROC curves were plotted, where the y-axis represents true 
positive rate (TPR, sensitivity/recall) and the x-axis represents false positive rate or 1− 
specificity (FPR). Each outcome was evaluated based on the area under its ROC curve 
(AUC) where a value of 1 represents perfect discrimination and 0.5 represents 
performance at chance level. AUC is a threshold-independent measure of overall 
classification accuracy. Accuracy, precision, recall, and F-Measure were calculated for 
each model as additional indicators of classifier performance.  
The performances of our classifiers were compared to the results of the same 
analysis when using clinical-only features and the results reported by Oen et al (69). The 
latter included predominantly clinical predictors at enrollment including: age, sex, JIA 
subtype, pain score, active joint count, number of active joints with limited range of 
movement, PGA, patient or parent global assessment of overall well-being measured on a 
10-cm visual analog scale, CHAQ, JAQQ, ESR, and c-reactive protein CRP (69).  
4.8 Results 
 From an initial set of 112 features, uninformative and redundant features were 
removed using CFS and ReliefF. As a result, 31 features were selected. The final sets of 
features for predicting each outcome are shown in Table 4. 2 In addition to clinical 
disease manifestation, eight inflammation-related biomarkers including pro-inflammatory 
IL-1α, IL-10, IL-15, IL-12p70, IL-17, TIMP-4, GM-CSF, and VEGF were identified as 
predictors. Wrist joint involvment and IL-12p70 were common predictors among all 
outcomes. Foot joint involvment, number of active joints and number of effused joints, 
white blood cell count (WBC), ESR, and IL-1α were shared as predictors by both 
outcomes 1 and 2 (Table 4.2). The selected features were used as input for the random 
forest algorithm.  
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Eighteen months after diagnosis, 33%, 37%, and 26% of patients had active 
disease in defined outcomes 1, 2, and 3, respectively. For each outcome, the random 
forest classifier was trained. Characteristics of the classifiers’ performances are listed in 
Table 4.3 and illustrated in ROC curves (Figure 4.1). Classifiers predicted arthritis 
activity outcome, PGA, and Wallace outcomes with 79%, 82%, and 71% accuracy, 
respectively. When considering presence/absence of active joint as the outcome, the 
classifier achieves a higher specificity. In contrast, other performance measures (AUC, 
sensitivity, precision, and F-measure) were slightly higher when PGA was used as the 
disease outcome. Wallace outcome had the lowest predictive performance. 
 
Table 4.2 Predictive features. 
Features at first presentation predictive of active arthritis, physician global assessment 
(PGA), and Wallace criteria outcome at 18 months.  
 
IL, interleukin; VEGF, vascular endothelial growth factor; TIMP-4, tissue inhibitor 
of metalloproteinase; GM-CSF, granulocyte macrophage colony-stimulating factor; 
WBC, white blood cell counts; ESR, erythrocyte sedimentation rate. 
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Table 4.3 Performance measures of classifiers. 
Combined clinical and biological predictors and clinical predictors only for 
the outcome 1 (active arthritis) and the outcome 2 (Physician Global Assessment [PGA]), 
and the outcome 3 (Wallace criteria).  
 
  AUC, area under the curve; CI, confidence interval. 
 
The same analysis was applied to the clinical characteristics of the patients. Table 
4.4 shows the clinical predictors of the three outcomes. The performances of clinical 
predictors are shown in the Table 4.3, which alone were not as satisfying as performances 
of clinical and biological predictors combined.  
The performances of the identified classifiers in Table 4.2 were compared with 
those of the previous study (clinical predictors) reported by Oen et al. (Figure 4.1) (69). 
Results indicate that the former predicts outcomes more accurately than the latter.  
 
 
 Performance                    
measures  
 
Classifiers Outcomes 
Active arthritis 
(n=88)  
PGA 
(n=93) 
Wallace criteria 
(n=54) 
AUC Clinical-Biological 
 
0.83 0.86 0.82 
Clinical 
 
0.76 0.79 0.67 
F-measure 
 
Clinical-Biological 
 
0.79 0.82 0.7 
Clinical 
 
0.71 0.75 0.65 
Generalization  
error 
Clinical-Biological 
 
0.23 0.20 0.29 
Clinical 
 
0.27 0.26 0.35 
Accuracy 
(CI) 
 
Clinical-Biological 
 
79% 
(0.317-0.142) 
82% 
(0.281-0.118) 
71% 
(0.477-0.222) 
Clinical 
 
72% 
(0.362-0.177) 
74% 
(0.349-0.170) 
65% 
(0.399-0.160) 
Precision 
(CI) 
 
Clinical-Biological 
 
79% 
(0.654-0.871) 
82% 
(0.732-0.914) 
72% 
(0.384-0.758) 
Clinical 
 
73% 
(0.615-0.839) 
75% 
(0.596-0.814) 
65% 
(0.384-0.758) 
Specificity 
(CI) 
Clinical-Biological 
 
76% 
(0.670-0.878) 
82% 
(0.708-0.904) 
57% 
(0.509-0.823) 
Clinical 
 
72% 
(0.609-0.839) 
70% 
(0.603-0.817) 
57% 
(0.458-0.798) 
Sensitivity 
(CI) 
Clinical-Biological 
 
          
79% 
(0.716-0.920) 
82% 
(0.732-0.914) 
71% 
(0.615-0.974) 
Clinical 
 
73% 
(0.615-0.842) 
75% 
(0.684-0.889) 
65% 
(0.483-0.867) 
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Table 4.4 predictors of the three outcomes. 
Features at first presentation predictive of active arthritis, physician global assessment 
(PGA), and Wallace criteria at 18 months when applying the models on clinical-only 
features.  
 
WBC, white blood cell; ESR, erythrocyte sedimentation rate. 
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Figure 4.1 Receiver Operating Characteristic (ROC). 
ROC curve for clinical and biological predictors (A) and clinical predictors (B) for 
outcome 1 (active arthritis-upper), outcome 2 (PGA-middle), and outcome 3 (Wallace 
criteria-lower). The diagonal line denotes the expected performance of a tool that uses 
random guessing. 
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4.9 Discussion  
Using a composite panel of clinical and biomarker features in JIA patients at first 
presentation, we found improved prediction of short-term disease outcomes compared to 
historic clinical features alone.  
The panel was developed from a set of clinical and biomarker attributes by 
applying feature selection and random forest techniques. Random forest is a robust 
machine learning classification algorithm that can investigate prediction power of 
features in a compound (quantitative or categorical) and high-dimensional dataset. It is 
among the most accurate methods of classification and permits both a measure of the 
relative importance of features and prediction. Previous studies have focused on the 
utility of clinical or laboratory characteristics of patients separately (341). Among clinical 
and laboratory predictors of JIA outcomes previously reported (36, 38, 62, 68, 69) our 
analysis confirmed only active joint count, effused joint count, wrist involvement, age at 
disease onset, systemic JIA rash, and ESR, and added foot joint involvement, WBC, and 
platelet counts as the clinical predictors in the composite panel.   
 The cytokine profile we identified is pertinent to JIA. IL-1, a pathogenic cytokine 
in systemic JIA (100) is among the predictive biomarkers, an observation that aligns with 
systemic JIA rash, a sign of active disease, being among the clinical predictors. It has 
been suggested that IL-15 may trigger the overproduction of IL-17 in joints of 
rheumatoid arthritis patients (342). IL-17 expressing T cells are abundant in JIA joints 
and correlate with number of involved joints (343). Increased IL-17 levels in synovial 
fluid of patients with ERA correlate with disease activity (12). IL-12p70 promotes the 
induction and activation of both Th1-cells and Th17-cells, key mediators in the 
pathophysiology of JIA (344). Yamasaki et al. showed that VEGF is an indicator of 
disease activity in oligoarticular and polyarticular JIA in remission and can be employed 
as a marker for guiding, tapering, or discontinuing treatment (345). Ramamurthy et al. 
reported an association between experimental systemic arthritis in rats and elevated 
gingival tissue MMPs that was reversed with TIMP-4 gene therapy (346). GM-CSF 
stimulates the production of macrophages and is an inflammatory mediator in JIA. 
Therapeutic antibodies targeting the GM-CSF receptor chain may be a viable therapeutic 
option in treatment-resistant JIA (347, 348). 
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Van Dijkhuizen et al. showed that in a cohort of JIA patients outcomes could not 
reliably predict inactive disease in the entire cohort using clinical, cytokine, and 
microbiome inputs (334). However, when certain JIA categories were considered 
separately (oligarticular, RF-negative polyarthritis and ANA-positive), prediction of 
inactive disease was moderately robust. In this current study, we did not investigate 
predictors for individual JIA categories as the number in each group was small.  
If we use only clinical characteristics, a higher number of predictors was needed 
to reach acceptable test performances but considering a combination of clinical and 
biomarker features resulted in a higher classifier performance than clinical data only. 
 Somewhat unexpectedly, systemic JIA rash but not systemic JIA fever was a 
predictive clinical feature, and IL-1α but not TNF-α a predictive biomarker. In the 
analytical frameworks applied, elimination of features having equal importance (fever 
and systemic rash and TNF-α and IL-1α) might account for the unanticipated exclusion of 
certain features. Finally, it should be noted that JIA ILAR category was not retained as a 
predictor in any of the models. This observation could suggest that JIA categories might 
not align precisely with category-specific pathobiological process that mediates 
outcomes. 
Medications started at enrollment and continued to 18 months included 
nonsteroidal anti-inflammatory drugs (NSAIDs) for 89 (95%), DMARDs for 57 (50%), 
prednisone for 25 (29%), and intra-articular corticosteroid injections in 7 (7%) patients. 
Biologically-based medications were prescribed at approximately 6 months post-
enrollment in 18 patients (19%). As there were insufficient numbers of patients to stratify 
into on/off a particular treatment group, effects of medication on outcomes were not 
assessed in this study. 
The results of this study, if confirmed in an independent JIA validation cohort, 
could help inform the development of a clinically useful tool for early prediction of JIA 
outcomes and thereby aid in treatment selection. We found that readily accessible clinical 
measures alone had reasonable performance statistics. However, while adding biomarkers 
improved accuracy and should add a more personalized approach to assessing individual 
patients, reliable biomarker analyses are not easily accessed in current routine clinical 
settings. Until such time as evidenced-based, comprehensive, and personalized biomarker 
assessments become integrated into usual clinical care a two-step approach to 
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prognostication and treatment selection could be applied. Under such a model clinical 
feature could be considered first in all patients and then, if indicated, targeted biomarker 
assessments undertaken with reference to the respective clinical contexts.  
4.10 Study limitation 
Fluctuations in biomarkers can be influenced by diurnal variations, physical 
activity, sleep, and food intake (327), features that were not controlled for in this study. 
Recent studies suggest joint ultrasound features are predictive of inactive disease (349); 
however, we did not include imaging as a potential outcome predictor. Further, this study 
did not include a validation cohort; the generalizability of the results requires validation 
in an independent cohort of children with JIA.  
Our study did not include genetic markers (HLA and single nucleotide 
polymorphisms, as examples) or gene expression and metabolomics profiling. 
Considering these additional biologic markers could further enhance and refine panels of 
outcome predictors. In this study, we used three clinical indicators of disease activity; a 
broader array of outcome measures and longer duration of follow-up should further 
strengthen the reliability of clinical-biomarker predictive panels.  
4.11 Conclusion 
Supervised machine learning algorithms are enabling us to overcome limitations 
of conventional statistical models especially when large datasets are available in 
relatively small study populations. We proposed a model that can evaluate the predictive 
ability of a relatively small panel of clinical measures and inflammation-related 
biomarkers simultaneously. We have shown that combined clinical and biological 
measures of JIA shortly after diagnosis can be used to predict clinically important 18-
month outcomes.  
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CHAPTER 5 
OVERALL DISCUSSION AND CONCLUSION 
The studies presented in this thesis were designed to develop and assess new 
approaches for categorizing and predicting outcomes of chronic childhood arthritis. 
Biologically-based characteristics of JIA patients in concert with clinical disease 
manifestations were used to identify and characterize distinctive subgroup clusters and 
ascertain their alignments with conventional JIA taxonomy (Chapter 3). These same 
patient characteristics were investigated as short-term JIA outcome predictors (Chapter 
4). Since Chapters 3 and 4 each includes a discussion section, this present chapter 
provides a general overview and discussion of sample characteristics, methods, and 
findings of both studies in the context of the literature reviewed in Chapter 1. Finally, this 
chapter includes concluding remarks relating to the entire study’s strengths, limitations 
and implications for clinical practice and future research. 
5.1 Study participant characteristics 
Data were derived from a Canadian prospective longitudinal inception cohort 
(The BBOP Study) comprising children with new-onset JIA who were enrolled within six 
weeks of first presentation to the pediatric rheumatology care service. Initially 186 JIA 
participants were enrolled in the BBOP study. However, some participants did not 
complete all BBOP study elements. As a consequence, 150 participants were included in 
the categorization study (Study 1; Chapter 3) and 96 were included in the prediction 
study (Study 2; Chapter 4) (Table 5.1). Due to BBOP selection criteria explained in the 
following section (5.2) the prevalence of BBOP patients by design differ from the typical 
distribution of JIA categories in North American JIA clinic populations. 
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Table 5.1 The number of participants in each JIA category in Studies 1 and 2 compared to 
the JIA category distribution in typical clinical populations (350).  
 
      ERA, enthesitis related arthritis. 
5.2 Sample characteristics 
The demographic characteristic of participants in both studies the categorization 
study (Study 1) and the prediction study (Study 2) were similar (Table 3. 2). Females 
predominate in JIA cohorts (female/male ratios ranging from 2 to 6:1 depending on the 
JIA category) as was the case in our study population (350, 351). 
Oligoarticular and RF-positive polyarthritis JIA categories tend to predominantly 
affect girls while ERA has a higher frequency in boys. Sex distribution within JIA 
subgroups in study 1 cohort follows the expected trend (Table 5. 2). 
In North America 50-80% of JIA patients are affected by oligoarthritis while 
15%-20% of patients have polyarticular subtypes. However, because of BBOP’s 
recruitment strategy, the number of patients with oligoarthritis in our cohorts is 
proportionately lower than those having polyarthritis. BBOP aimed for a reasonable 
number of participants in each of seven JIA subgroups rather than aspiring to achieve a 
typical JIA subgroup distribution. To achieve this, only participants with polyarthritis or 
systemic JIA, the least common categories, were eligible during the first six months of 
the enrollment period; after six months and until the end of the two-year enrollment 
period participants with any JIA subtype were eligible. 
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Table 5.2 Sex distribution of JIA categories in study 1.  
 
      ERA, enthesitis related arthritis. 
In the current studies the average age distribution of the patients in JIA categories 
were oligoarthritis (mean 4.8), RF-positive polyarthritis (mean 11.4), RF-negative 
polyarthritis (mean 6.2), psoriatic arthritis (mean 9), ERA (mean 11.4), systemic arthritis 
(mean 7.4), undifferentiated arthritis (mean 7.4). Mean and Median age in the BBOP 
study are: oligoarthritis (mean 7, median 6), RF-positive polyarthritis (mean 10, median 
13), RF-negative polyarthritis (mean 10, median 11), psoriatic arthritis (mean 12, median 
13), ERA (mean 10, median 12), systemic arthritis (mean 9, median 9), undifferentiated 
arthritis (mean 12, median 13). 
In summary, the sex ratio and ages of participants in both studies are 
representative of the typical JIA populations. The distribution of JIA categories, by 
design, differed from the typical JIA population. 
5.3 Data pre-processing  
The analyses began by pre-processing data including dealing with missing values, 
removing outliers, and log- and Z-transformation. There were cases where missing values 
were concentrated in certain variables. MMP7, a biomarker for which there was 
substantial missing data (<60% available data), was removed from the dataset. Missing 
values of the other variables were distributed randomly. Biomarker variables (continuous 
variables) had missing values completely at random. To retain as much data as possible in 
the analysis, multiple imputation was done using SPSS. Multiple imputation was done for 
variables with ≤40% missing values. To impute missing data in several variables a 
multivariate model should be fitted to all of the variables with missing values. SPSS 
default method was used, which scans the data to determine the best imputation method. 
For continues variables linear regression is the default method.  
Resolving missing values is important for generating correct hypothesis testing 
and making valid inferences, while in predictive models’ accuracy is the main concern. 
   
 
82 
In normal conditions, blood concentrations of cytokines are low or undetectable. 
However, there is no reliable information about upper limits of normal for respective 
cytokines under various physiological states influenced, for example, by diurnal 
variations, physical activity, nutrition, or sample collection, processing and storage. In the 
presence of inflammation, extracellular and intracellular cytokine concentrations 
increase. 
Data pre-processing is an important step before analysing biological data. There 
were some data points in cytokine levels that diverge from the overall pattern of the data. 
They had influential effect on regression analysis and cause the coefficient of 
determination to be bigger (R2=0.963 with outliers and R2=0.388 without outliers). Thus, 
outliers were removed. Although removal of outliers improves data stability there was no 
evidence in our study that the biomarker outlier values were a consequence of technical 
issues or other artifactual influences rather than accurate biomarker measures.  
Data reduction and variable selection techniques are another class of data 
transformation. For the clustering study, PPCA was applied and for the prediction study 
CFS and ReliefF methods were used. We used a probabilistic PCA algorithm for data 
reduction. The conventional PCA method for data reduction defines a linear projection of 
the data and cannot handle categorical or binomial data; PCA cannot be applied to mixed 
datasets comprising various data types. Due to lack of association with a probabilistic 
model, the scope of applications for using PCA is limited and can fail to reveal latent data 
structure as large data may comprise a mixture of two or more Gaussian distributions 
with common covariance. By using PPCA, variables were reduced into three uncorrelated 
components, which were used for clustering. In the prediction model, we needed to find 
variables that possess reliable predictive power that can be simply implemented in the 
clinical setting. As the number of variables retained in the PCs was large, feature 
selection methods were applied. 
In summary, data pre-processing methods used in this study enabled us to create a 
smaller dataset that was easier to work with while still yielding robust and informative 
results. 
5.4 Principal components 
Three PCs have been retained, each containing variables with maximum 
correlation. The first PCs from visit 1 and 2 (PC1a and PC2a) were explained by levels of 
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pro/anti-inflammatory cytokines, interferons, and growth factors. The biomarkers 
retained in the first PC in both visits comprised: G-CSF, GM-CSF, VEGF, IFN-γ, IFN-α, 
IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IL-1α, IL-1Ra, IL-2, IL-4, IL-5, IL-6, 
IL-7, TNF-α, and TNF-β. 
Cytokines mediating Th1 and Th2 immune responses are retained in the first PC. 
Although these two cytokine pathways tend to be antagonist to each other our data 
suggest a positive correlation between these two pathways at enrolment and also 6 
months later. 
As an example of inflammatory joint disease, adult patients with early arthritis 
who develop RA have a distinct but transient synovial fluid cytokine profile, which does 
not persist. In early RA synovial fluid elevated levels of IL-1, IL-2, IL-4, IL-13, IL-15, 
and IL-17 are found within 3 months after symptom onset, compared with early arthritis 
patients who do not develop RA (352). IL-6 was present in all type of all inflammatory 
arthritis (352). Our results show high levels of both Th1 and Th2 cytokines, which 
change over time and are more biased toward Th1 when the disease is well-established. 
Longer-term follow-up studies should help reveal changes in cytokine profiles in 
different JIA categories over time. 
An essential mechanism in the pathogenesis and persistence of RA, and probably 
JIA, is angiogenesis (353, 354). Oxygen and nutrients necessary for metabolism of high 
metabolic cells involved in the arthritic process are delivered via new vascularization. 
Growth factors, mainly VEGF, induce angiogenesis which starts very early in the arthritis 
process (353). Biomarkers that modulate angiogenesis (353). Biomarkers that modulate 
angiogenesis have been associated with pathogenesis, severity, and progression of JIA 
(354). VEGF correlates with the degree of inflammation in JIA patients (354). Serum 
levels of G-CSF and GM-CSF, which regulate hematopoiesis, are elevated in RA and 
correlate with measures of disease. Comparable to studies in RA, early imbalance of 
grow factors are evident from our results (355). Future studies are required to determine 
if levels of growth factors in JIA reflect disease activity. 
Clinical characteristics of JIA together with PGA were grouped in the second PC 
at enrolment and the third PC at the 6-month visit. At enrolment, clinical data and levels 
of MMPs, MIP, and TIMP were retained together in one PC, while at the 6-month visit, 
the same cytokines along with specific clinical findings of systemic arthritis retained in 
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one PC. Clinical findings in patients with active systemic JIA (such as serositis and 
hepatosplenomegaly) grouped with MMPs suggesting that these cytokines might be 
markers reflective of disease activity in systemic JIA. The regulation of MMP-1, 3 and 
TIMP1 in synovial fluid of JIA patients has previously been studied. The finding revealed 
that regardless of JIA category and age groups, degradation of type II collagen is present 
early in the disease (218). MMPs pathways mediate cartilage and bone remodelling (19, 
356). 
At enrolment, the third PC retained some of the features of systemic disease (skin 
rash and fever) together with conventional measures of disease activity such as WBC, 
ESR, CRP, and platelet count while the same measures grouped with the number of 
active and effused joints and PGA 6 months later. Again, these findings show that 
conventional measures of disease activity are reliable; however, their importance might 
fluctuate in various stages of the chronic arthritis. 
In summary, the PCs recovered three important aspects of JIA, clinical 
manifestations, underlying biology, and laboratory markers. Three PCs were used as new 
variables for clustering patients in the first study.  
5.5 Clustering 
The aim of this study was to identify panels of clinical and biomarker attributes 
that could define homogenous chronic childhood arthritis disease categories. According 
to ACR and ILAR criteria, disease duration of 6 months is required to determine the 
JRA/JIA disease categories based predominantly on clinical manifestations. When 
considering biological factors in conjunction with clinical features for classifying disease 
subtypes a similar temporal trajectory to assigning subtypes is required; we found 
patients aligned with one of three Clusters at enrollment but were assigned to one of five 
Clusters six months later. 
The purpose of a disease classification system is to identify differences among 
patients using measurable, discretely defined metrics. Although clinical manifestations 
are measurable, they can be prone to inter-observer variations. Considering both clinical 
and biological characteristics when categorizing patients should lead to a more refined 
disease taxonomy. 
The finding of three Clusters at enrolment and five Clusters six months later is 
consistent with the current notion that time is required for children with chronic arthritis 
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to settle into more representative subcategories of the disease. Augmenting clinical 
characteristics with biomarker profiling at the time of diagnosis should contribute to 
informing more rationally conceived, biologically-based treatment interventions resulting 
in mitigation of disease progression. 
Children with RF-negative polyarthritis seem to have two clinical trajectories. 
Disease course and manifestations of ANA-positive, RF-negative polyarthritis patients 
are comparable to those with the oligoarthritis subset (357). New Clusters in visit one 
also divided RF-negative polyarthritis patients mainly into two subgroups (Figure 4.4); 
almost half were aligned with oligoarticular patients in Cluster-1a while the other half 
grouped with RF-positive and systemic arthritis patients in Cluster-1b. The statistical 
differences that distinguished the two subsets of RF-negative patients included number of 
active and effused joints, CRP, MMP-1, 8, 9, TIMP-4, EGF, GM-CSF, IP10, TNF-α, IL-
6, IL-1α, and IL-1Ra. The subset of RF-negative patients in Cluster-1a has fewer 
involved joints and lower levels of inflammatory biomarkers compared to those that 
grouped in Cluster-1b. Only 4 of 50 patients with RF-negative arthritis who had the 
highest levels of inflammatory biomarkers grouped into Cluster-1c. These three subsets 
of the patients did not have significantly different frequencies of ANA-positivity. The 
findings reveal that at least two distinct subsets, defined by clinical and biomarker 
features, can be discerned from within the conventional RF-negative polyarthritis JIA 
category. 
In Visit 1, when considering ANA-positive patients with psoriatic arthritis, 
oligoarthritis, RF-negative polyarthritis, and undifferentiated JIA, 100%, 78%, 42%, and 
57% respectively were retained in Cluster-1a. The dataset included 66 ANA-positive 
patients at visit 1; of these 57% were grouped in Cluster-1a, 28% in Cluster-1b, and 
13.6% in Cluster-1c. Earlier report have posited that ANA-positive patients assigned to 
different JIA categories actually constitute a homogeneous patient population with 
similar characteristics (51, 301, 302); our results support this suggestion as ANA-positive 
patients in our cohort tended to align together (51). 
Patients received a single medication or a combination of medications including 
NSAIDs (mainly Naproxen, n=120), DMARDs (only Methotrexate, n=41), and 
corticosteroids (oral, n= 41or intra-articular, n=29). Only two patients in our cohort were 
treated with biologic agents. There were different responses to the same treatment 
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regimen, even within each apparently homogenous JIA category. For example, of two 
patients with RF-positive polyarthritis who had received Naproxen and Methotrexate 
during the first 6 months, one Clustered into the group with high levels of biomarkers, 
higher measures of disease activity, and higher number of active joints, while the other 
experienced mild disease activity after 6 months and Clustered into a group with similar 
characteristics. Thus, disease course and response to therapy might not be consistently 
predictable in the context of the current JIA taxonomy. Having a classification system 
based on the underling pathophysiology of the disease might be expected to lead to 
development of more biologically-based, personalised treatment interventions. 
5.6 Predicting outcome  
The importance of biomarkers in the pathophysiology of JIA lead us to investigate 
whether a composited panel of clinical and biomarker variables in patients at disease 
onset could predict short-term disease outcomes. A number of studies have elucidated 
predictors of JIA prognosis. Adib et al. (2005), and Dijkhuizen et al. (2018) noted 
substantial variances in the prognosis even within JIA categories (23, 334). However, to 
reduce that variance Wallace et al. developed and validated a set of criteria for disease 
remission (26, 29, 358, 359). However, these criteria were derived mainly in relation to 
polyarticular, oligoartricular, and systemic JIA. 
Clinical measures of active arthritis such as joint swelling, warmth, tenderness 
and pain on motion, together with PGA are applied as indicators of disease activity and 
outcome variables in almost all JIA predictor studies. Consequently, in our study, we 
defined outcomes as 1) presence/absence of clinical manifestations of active arthritis, 2) 
PGA, and 3) Wallace criteria. The first two outcome measures are easily determined in 
the clinic setting and are more responsive than functional ability and laboratory measures 
(360). Responsiveness is an element of validity and defined as how a clinical measure is 
sensitive to change over time or between groups (361).  
Wallace outcome criteria is an accepted outcome measure among clinicians and 
include both absence of active joints and PGA score together with no fever, rash, 
serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, no active 
uveitis, and normal ESR or CRP (29).  
A number of potential outcome predictors have been suggested by various studies. 
The most commonly suggested predictors are disease activity parameters, sex, age, active 
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disease duration and severity, JIA categories, HLA type, ANA, RF, WBC, ESR, CRP, 
and patients’ socio-economic status (37, 67-69, 71, 76, 78, 85, 362-364). However, some 
of these variables, such as demographic and laboratory measures, are not valuable 
predictors because they show too much variability. Disease activity parameters, such as 
the number of active joints at onset, PGA, the parent or patient global assessment, CHAQ 
score, and symmetric joint involvement were identified as valuable outcome predictors. 
Other potential predictors such as cytokine levels in blood or synovial fluid, and genetic 
markers, like HLA and SNPs in genes associated with the immune system are seldom 
applied as outcome predictors in the clinical setting. Many of the predictor studies were 
retrospective and used univariate analysis, consequently. Thus, they were prone to 
selection bias and failed to effectively exclude confounding factors. 
In a prospective cohort study, Guzman et al predicted JIA severe disease course 
by assessment of quality of life, pain, medication requirements, patient-reported side 
effects, and active joint counts (365). They identified four disease courses in JIA based 
on variables derived from clinical experience. In 2011, ACR published recommendations 
for JIA treatment informed by features putatively predictive of a poor prognosis. Their 
predictors were evidence-based and were shown to correlate with outcome but were not 
applied to predict outcome (231). 
Earlier studies analyzed clinical or laboratory characteristics separately and used 
univariate analysis which describes the linear relationship between two variables. A 
number of investigations were correlation studies that did not identify predictors; 
correlation analysis simply detects an association between two variables, which may 
reflect that they are related to an unknown factor, or another variable. 
In study 2, the predictive powers of clinical, laboratory, and inflammatory 
biomarkers have been evaluated using random forest, a robust classification algorithm 
with good accuracy (293, 295). Random forest is the best choice when the number of 
predictor variables is greater than the number of subjects. Logistic regression has less 
power to deal with this situation as the degrees of freedom increase dramatically 
including higher-order interactions in the model (366). Random forest provides a measure 
of the relative importance of variables that is helpful for selecting a small number of key 
predictors. 
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The classification tree algorithm rapidly selects significant features resulting in a 
classification tree with binary split criteria and enables automatic classification, for 
instance lung cancer patients and control subjects based on their individual genetic 
profile. Logic regression is a generalized regression methodology for predicting the 
outcome in classification and regression problems based on Boolean combinations of 
logic variables. Even though a logic regression is able to include continuous covariates, 
the predictors must be binary in order to be considered as a Boolean combination. This 
can be somewhat limiting when compared to other tree-based classifiers. 
Results of the current study identify factors that are predictive of active arthritis 
and PGA 18 months after the first presentation of JIA including number of active and 
effused joints, wrist and foot joint involvement, age, ESR, WBC, systemic rash, IL-1α, 
IL-10, IL-17, IL-15, IL-12p70, VEGF, GM-CSF, and TIMP-4. 
Number of active joints is the most prominent clinical manifestation of the disease 
and considered as a criterion for JIA classification, prediction and disease activity 
outcome measure (2, 38, 61, 69). Al-Matar et al. and Magin-Manzoni et al. have shown 
that wrist involvement is among the best predictors of long-term IJA outcome predictors 
(30, 63). Age at onset, wrist involvement, and number of active joints during the first 6 
months of disease, ESR, and systemic arthritis manifestations were previously reported as 
outcome predictors in JIA (36, 38, 62, 68, 69). Our results are in concordance with these 
studies. 
JIA categories and age at onset usually served as proxies for one another. For 
example, oligoarthritis has a peak age range of 2-4 years, RF-positive polyarthritis 
disease and ERA occur mostly during late childhood or adolescence, RF-negative 
polyarthritis has biphasic distribution with a peak in early childhood (2-4 years of age) 
and later peak (6-12 years of age), and psoriatic also with a biphasic age distribution 
(early peak at 2-4 years of age and later peak at 9-11 years of age). Systemic JIA has no 
particular age predominance. Young age at onset has been reported as a predictor of 
persistent disease and joint erosions (38). In addition, associations between certain HLA 
allotypes and onset age have been reported. HLA-DR11 and HLA-DR13, are more often 
observed in patients with younger onset age (less than 6 years old), while HLA-B27 and 
HLA-DR4, and are associated with protection early in life but with increased risk of 
disease later in childhood (224). The disease-predisposing HLA-DRB1/DPB1 alleles 
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(including: DRB1*0801; DQA1*0400; DQB1*0402, DRB1*1103/4; DQA1*0500; 
DQB1*0301, and DRB1*1301; DQA1*0103; DQB1*0603) were observed in 78% of 
patients with JIA onset age ˂6 years. Frequency of these alleles occurred in 68% of 
patients with oligoarticular JIA with disease onset age≥6 years. DRB1*0801 was reported 
with increased frequency in JIA children with polyarthritis whose onset was 6 years or 
older (367). 
ESR is a marker of both systemic and organ-specific inflammation. It is one of the 
ACR core set criteria for definition of improvement. In a Nordic population-based JIA 
study, ESR showed strong correlation with disease activity in JIA (27). It also has been 
identified as a predictor of persistent disease and joint erosions in long term studies (38). 
Long duration of elevated ESR within the first 6 months is a risk factor for the absence of 
remission at follow-up (69). Long duration of elevated ESR within the first 6 months is a 
risk factor for the absence of remission at follow-up (69). Elevated ESR>35 mm at 
disease onset is reported to be a predictor for the occurrence of uveitis 2-3 years later 
(368, 369). 
The study 2 indicates that arthritis involving foot and wrist, together with eight 
biomarkers (IL-1α, IL-10, IL-15, IL-17, IL-12p70, TIMP-4, GM-CSF, and VEGF) 
collectively predict short-term arthritis activity in JIA. 
Imbalance in the pro/anti-inflammatory cytokines is the main underlying 
pathogenic process in arthritis. IL-1 is an important biomarker in the pathogenesis of 
arthritis (370). In systemic JIA dysregulation of IL-1 production plays a critical 
pathogenic role. Pascual et al. have shown that the serum of patients with systemic JIA 
up-regulates the expression of IL-1α and IL-1β genes by healthy peripheral blood 
mononuclear cells and treatment with IL-1Ra efficiently treats the disease (16). 
Biologically active pro IL-1α, which is released from cells in systemic JIA, is a 
main activator of acute inflammatory responses. IL-1α is important in arthritis 
development and progression; levels of membrane-bound IL-1α correlate with the 
severity of arthritis in a mouse model. RA patients who have higher levels of anti-IL-1α 
antibodies develop less destructive joint disease. SNPs in IL-1R2, IL-1α, IL-1F10 and IL-
1RN genes are linked to systemic JIA (100). Ravindran et al. found a higher frequency of 
the IL-1α polymorphism in adult Caucasian patients with psoriatic arthritis (371). 
Rahman et al. noted that the IL-1 gene, with at least 2 independent regions, appears to be 
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a high-priority susceptibility locus in psoriatic arthritis (100, 102). IL- 1 and TNF-α 
enhance cartilage degradation by inducing MMP-3 and MMP-1 expression, but not TIMP 
expression (372). Agarwal et al. noted that ERA and polyarticular JIA patients have 
elevated IL-17 levels in their synovial fluid, which correlated with measures of disease 
activity. They suggested that IL-17 might play an important role in pathogenesis of 
synovitis in these patients. IL-17 also specifically induces MMP expression in ERA 
synovial fibroblasts, without inducing TIMP, suggesting a role of this cytokine in 
cartilage destruction (12). The T cell subset that produces IL-17, IL-21, and IL-22 (the 
Th17 subset) is more abundant in the joints of JIA patients compared with their blood. 
There are significantly higher numbers of Th17 cells type in the synovial infiltrate in the 
joints of children with extended oligoarticular JIA than in those with persistent 
oligoarticular JIA (343). There is a notion that IL-15 may trigger the overproduction of 
IL-17 in joints of rheumatoid arthritis patients. IL-12p70 promotes the induction and 
activation of both Th1-cells and Th17-cells and IL-12B (a subunit of IL-12p70) gene was 
associated with the development and disease severity of ankylosing spondylitis in adults 
(344, 373). 
Vignola et al. noted that VEGF levels in synovial fluid of JIA patients are higher 
than serum. They suggested that this factor may have a major role in the outgrowth of 
hyperplastic pannus and tissue damage in JIA (374). A strong correlation between serum 
VEGF levels and disease activity in polyarticular patients has been found suggesting the 
importance of VEGF in joint inflammation (375). Yamasaki et al. showed that VEGF is 
an indicator of disease activity in oligoarticular and polyarticular JIA in remission. They 
suggested that this biomarker can be employed as a marker for guiding tapering or 
discontinuing treatment (345). 
There are a limited number of studies that considered biomarkers and genes 
together as predictors of outcome in JIA. Oen et al. found significant correlations 
between pain and IL-6 genotypes; between PGA and IL-10 genotypes; and between joint 
space narrowing on early radiographs and TGF-1and IL-10 genotypes using univariate 
analysis. In the same study, multivariate analyses revealed that only IL-6 genotype was 
significantly correlated with pain scores (20). Another genetic study revealed that 
polymorphism of RANTES gene is associated with an early relapse of childhood arthritis 
after clinical remission (374, 376). 
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Overall, the results of this study show the contributions that clinical and biologic 
profiles can have in predicting short-term JIA outcomes as indicated by arthritis activity, 
PGA, and Wallace criteria. 
5.7 Limitations 
Small sample size, particularly at the 6-month visit (study 1) and 18-month visit 
(study 2), limited the robustness of the analysis. For example, there was not enough data 
for indicators of functional capacity or quality of life 18 months after enrolment to 
consider as a potential JIA outcome. Due to sampling method during the first few months 
of the data collection, our cohort, by design, was not precisely representative of a typical 
JIA population. The variance of our study population from a typical JIA population might 
influence our results. For example, ANA was not identified as an important predictor 
variable. In contrast to the typical JIA population our cohort had more polyarthritis than 
oligoarthritis patients.  
We did not include HLA, genetic information, and radiologic measures of joint 
damage as potential outcome predictors. Lack of a validation cohort reduced the 
generalizability of the results. A longer duration of follow up and larger sample size 
could potentially increase the predictive power of the analysis. 
larger sample size could potentially increase the predictive power of the analysis. 
In addition to sensitivity analyses and cross-validation, the generalizability of the 
PCs and Clusters need to be evaluated by applying them in an independent cohort of 
children with chronic arthritis. To improve generalizability of the results, the validation 
cohort should be ethnically diverse, a goal that can best be achieved by multi-centered, 
international collaborations. In the present cohort, 75% of the study participants were of 
European lineage.  
Biomarker profiling is increasingly recognized as important for understanding and 
managing inflammatory diseases such as JIA. However, accurately detecting and 
quantifying biomarkers can be compromised by fluctuations in biomarker measures 
influenced by sample collection, processing and storage (303) and by influences of 
physiologic diurnal variations, physical activity, sleep, and food intake (377). Circadian 
variations in inflammatory biomarkers have not been evaluated in the context of 
childhood arthritis. A number of parameters can affect reliable measurements of 
circulatory levels of cytokines such as, timing of sampling, handling, storage, and 
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processing. Cytokines have a diurnal rhythm (378). IL-1, IL-6, TNF-α and IFN-γ peak 
early in the morning (379). Exercise also has an impact on the blood level of cytokines, 
for example physical activity increases release of IL-6 from muscle cells (380). The 
diurnal rhythm and exercise effect have not been considered in the current study. 
Determining whether variations in biomarker levels result from physiologic fluctuations 
or reflect disease activity requires further study.  
Plasma and serum should be separated soon after blood draw and be frozen at  
-80°C within 1 hour after blood draw. Interruption in sample processing may cause 
degradation, absorption, or cellular production of cytokines (381). Another consideration 
is the type of the blood collection tubes. Sodium heparin tubes show more consistent 
cytokine recovery than EDTA tubes. In this study, P100 tubes were used, which contain 
spray-dried K2EDTA anticoagulant (377). Earlier studies have shown that the integrity of 
cytokine measures are retained over longer periods of time using P100 tubes (303, 305-
307). 
5.8 Conclusion 
Emerging insights into underlying pathobiologic processes in JIA provide 
opportunity to predict and measuer disease outcoms. Supervised machine learning 
algorithms provide opportunities to overcome limitations of conventional statistical 
models especially in rare diseases with small numbers of patients and large amounts of 
data. Machine learning analytical frameworks can evaluate the predictive ability of a 
relatively small panel of clinical measures and inflammation-related biomarkers 
simultaneously.  
5.9 Future research 
Characterizing a broad array of biomarkers could inform refinements in JIA 
classification, treatment, and outcome prediction. We need to investigate methods that are 
reliable, simple to perform, economically reasonable, and robust for integrating 
biomarkers measurements into clinical practice. We have shown that clinical and 
biological measures of JIA shortly after diagnosis can be used to categorize and predict 
clinically important outcomes. Nevertheless, the present results suggest that further study 
of inflammatory biomarkers along with clinical manifestations of JIA in relation to 
patient outcome is warranted as they may prove to be useful prognostic markers. 
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There remains a need for the further evaluation of biomarkers and methods of 
selecting candidate biomarkers for JIA classification and outcome prediction. They need 
to be tested and validated in large patient cohorts. Reliable biomarker tests may assist 
with aiding treatment choices at disease onset, predicting response to medication and thus 
contribute to improving outcomes. They also can help to accurately identify patients who 
can safely stop medication once biological remission is reached. Another goal of 
biomarker profiling in childhood arthritis is to help to minimize adverse effects of 
treatments. To fulfill these goals, multi-centre and international collaborations are 
needed. 
We hope to continue this work with a larger cohort of JIA patients and with 
longer follow up to validate and extend these results. Then it will be possible to explore 
more thoroughly the utility of clinical and biomarker characteristics together to help 
refine approaches for diagnosing, managing, and predicting courses of JIA.   
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APPENDIX A 
Supplementary text 1 
Biomedical Research Ethics Board, University of Saskatchewan: #07-86; Clinical 
Research Ethics Board, University of British Columbia: #H07-01204; Health Research 
Ethics Board, University of Alberta: #6984; Biomedical Research Ethics Board, 
University of Manitoba: #H2007:111; Research Ethics Board, Hospital for Sick Children: 
#1000011118; Research Ethics Board, Children’s Hospital of Eastern Ontario: #09-16E; 
Biomedical Research Ethics Board, McGill University: #PED-07-020; Research Ethics 
Committee, Université Laval: #123.05.09; Institutional Ethics Committee of Research 
Involving Humans, University of Sherbrooke: #07-119; IWK Health Centre Research 
Ethics Board: #1001241; Human Investigation Committee, Memorial University: 
#06.047. 
Supplementary text 2 
Cytokine, chemokine, growth factor, and metalloproteinase plasma levels were 
assayed by bead-based immunoassays. Product codes for analytes (Milliplex, Milllipore 
Sigma) were as follows: RANKL (HBN51K1RANKL), RANTES (HCYTOMAG-60K-
01), OPG (HBN1B-51K-01), TIMP-1/2 (HTIMP1-54K-02), TIMP-3/4 (HTIMP2-54K-
01), MMP-3/12/13 (HMMP1-55K-03), MMP-1/2/7/9/10 (HMMP2-55K-05), MMP-8 
(HSP2MAG-63K-01), 29-plex cytokine/chemokine panel (HCYTMAG-60K-PX29), and 
FGF-2 (HCYTOMAG-60K-01). All bead-based analytes were analyzed on a 
Luminex100 LabMAP system (Luminex, Austin, TX; Analytical Facility for Bioactive 
Molecules, Hospital for Sick Children, Toronto) according to manufacturer’s instructions. 
sLRP1 was assayed in duplicate by ELISA as follows: 96-well micro-titer plates 
(Microlon, Greiner Bio-One Inc., Monroe, NC USA) were coated with 100 µl per well of 
monoclonal antibody specific for sLRP1 (clone α2-MRα2; Genway Biotech, San Diego, 
CA, USA), 1 µg/ml diluted in carbonate-bicarbonate (15mM Na2CO3, 35mM NaHCO3) 
with overnight incubation at 4oC. Plates were washed 3 times with 0.1% phosphate 
buffered saline (PBS; 0.14M NaCl, 1.5mM KH2PO4, 2.7mM KCl, 18.9mM Na2HPO4) 
containing 0.1% Tween 20 (PBST) and then 100 µl of plasma diluted 1/500 (or 1/1000, 
as needed to bring the sample ELISA values within the standard curve) was added to 
duplicate wells. After incubation at 37oC for 1 hour the plates were washed 3 times with 
PBST and 100 µl biotin-labeled anti-human LRP1 (Pierce, Thermo Scientific, and 
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Waltham, MA, USA) diluted 1:2500 in PBST was added. The plates were incubated for 1 
hour at 37oC, then washed 3 times with PBST. 100 µl of horseradish peroxidase (HRP)-
conjugated Avidin (Vector Laboratories, Burlingame, CA, USA) were then added at a 
1:5000 dilution for 30 minutes at room temperature. Plates were washed 3 times in PBST 
and 100 µl of the substrate (2 mM ortho-phenylenediaminine 0.02M citric acid, 0.05 M 
Na2HPO4, 0.012% H2O2) added. After a 30-minute incubation at 20oC, the reactions were 
terminated by addition of 100 µl of 4M H2SO4. Optical densities were measured at 492 
nm (Universal Microplate Reader EL800, Bio-Tek Instruments Inc. Winooski, VT, 
USA). Concentrations of sLRP1 were calculated based on a standard curve, which had a 
sensitivity of 1 ng/ml to 100 ng/ml. The standard curve was generated using sLRP1 
purified by affinity chromatography, using anti-sLRP (Genway Biotech, San Diego, 
USA) linked to Pierce NHS-Activated Agarose Slurry (Thermo Scientific, Waltham, 
USA). HMGB1 and vitamin D assays were performed as previously described (382, 383). 
 
A.1 Biomarkers that have a significantly different ranking in visit 1 Clusters. 
Biomarkers Clusters Mean Rank Chi-Square P value 
MMP-8 
V1.1 
V1.2 
V1.3 
60 
88 
98 
19.2 0.000 
MMP-10 
V1.1 
V1.2 
V1.3 
68 
76 
103 
9.5 0.009 
MMP-13 
V1.1 
V1.2 
V1.3 
73 
69 
108 
11.5 0.003 
TIMP-4 
V1.1 
V1.2 
V1.3 
68 
78 
98 
7.4 0.025 
FGF-2 
V1.1 
V1.2 
V1.3 
66 
72 
128 
30.4 0.000 
RANKL 
V1.1 
V1.2 
V1.3 
71 
71 
107 
10.7 0.005 
EGF 
V1.1 
V1.2 
V1.3 
64 
83 
96 
10.8 0.005 
Exotoxin 
V1.3 
V1.1 
V1.2 
60 
81 
120 
29.6 0.000 
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GCS-F 
V1.1 
V1.2 
V1.3 
55 
85 
129 
46.7 0.000 
GM-CSF 
V1.1 
V1.2 
V1.3 
51 
88 
136 
63.6 0.000 
IFN-α 
V1.1 
V1.2 
V1.3 
52 
85 
139 
63.3 0.000 
IFN-γ 
V1.1 
V1.2 
V1.3 
53 
84 
139 
60.9 0.000 
IL-10 
V1.1 
V1.2 
V1.3 
52 
86 
137 
60.4 0.000 
IL-12p40 
V1.1 
V1.2 
V1.3 
51 
88 
136 
64.0 0.000 
IL-12p70 
V1.1 
V1.2 
V1.3 
59 
77 
138 
48.3 0.000 
IL-13 
V1.1 
V1.2 
V1.3 
53 
84 
138 
58.8 0.000 
IL-15 
V1.1 
V1.2 
V1.3 
53 
86 
134 
56.0 0.000 
IL-17 
V1.1 
V1.2 
V1.3 
59 
78 
135 
44.5 0.000 
IL-1Ra 
V1.1 
V1.2 
V1.3 
47 
93 
135 
76.4 0.000 
IL-1α 
V1.1 
V1.2 
V1.3 
52 
85 
139 
61.1 0.000 
IL-1β 
V1.1 
V1.2 
V1.3 
57 
86 
115 
31.6 0.000 
IL-2 
V1.1 
V1.2 
V1.3 
53 
84 
137 
58.8 0.000 
IL-4 
V1.1 
V1.2 
V1.3 
58 
79 
138 
51.4 0.000 
IL-5 
V1.1 
V1.2 
V1.3 
59 
81 
126 
35.9 0.000 
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IL-6 
V1.1 
V1.2 
V1.3 
48 
92 
134 
69.9 0.000 
IL-7 
V1.1 
V1.2 
V1.3 
58 
79 
137 
49.1 0.000 
IL-8 
V1.1 
V1.2 
V1.3 
61 
82 
112 
22.2 0.000 
IP-10 
V1.1 
V1.2 
V1.3 
63 
82 
108 
17.4 0.000 
MCP-1 
V1.1 
V1.2 
V1.3 
64 
81 
103 
13.0 0.002 
MIP-1α 
V1.1 
V1.2 
V1.3 
54 
88 
123 
44.4 0.000 
MIP-1β 
V1.1 
V1.2 
V1.3 
56 
84 
129 
44.8 0.000 
TNF-α 
V1.1 
V1.2 
V1.3 
55 
83 
135 
51.7 0.000 
TNF-β 
V1.1 
V1.2 
V1.3 
52 
85 
141 
65.5 0.000 
VEGF 
V1.1 
V1.2 
V1.3 
55 
82 
139 
56.6 0.000 
HMGB-1 
V1.1 
V1.2 
V1.3 
68 
76 
103 
9.4 0.009 
sLRP-1 
V1.1 
V1.2 
V1.3 
64 
81 
103 
12.9 0.002 
1 
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A.2 Biomarkers that have a significantly different ranking in visit 2 Clusters. 
Biomarkers Clusters Mean Rank Chi-Square P value 
MMP-1 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
81 
56 
70 
108 
59 
27.5 0.000 
MMP-2 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
52 
79 
90 
78 
95 
22.4 0.000 
MMP-3 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
76 
58 
74 
130 
45 
68.2 0.000 
MMP-8 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
68 
83 
80 
109 
51 
30.5 0.000 
MMP-9 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
77 
62 
53 
122 
55 
47.6 0.000 
MMP-12 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
65 
59 
94 
119 
59 
43.0 0.000 
MMP-13 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
50 
68 
101 
127 
62 
65.2 0.000 
TIMP-1 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
86 
51 
76 
77 
79 
11.6 0.021 
TIMP-3 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
75 
70 
79 
104 
57 
19.5 0.001 
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TIMP-4 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
87 
64 
58 
106 
53 
30.8 0.000 
FGF-2 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
52 
72 
126 
123 
52 
76.1 0.000 
OPG 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
71 
60 
65 
131 
53 
61.6 0.000 
RANKL 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
78 
64 
85 
120 
42 
54.9 0.000 
EGF 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
72 
76 
87 
94 
59 
11.7 0.020 
Exotoxin 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
54 
83 
96 
106 
64 
31.1 0.000 
GCS-F 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
42 
96 
119 
119 
52 
85.5 0.000 
GM-CSF 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
49 
82 
118 
133 
42 
102.0 0.000 
IFN-α 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
42 
90 
134 
126 
45 
109.2 0.000 
IFN-γ 
V2.1 
V2.2 
V2.3 
43 
90 
131 
108.8 0.000 
   
 
123 
V2.4 
V2.5 
127 
44 
IL-10 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
38 
94 
127 
127 
49 
112.4 0.000 
IL-12p40 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
39 
93 
129 
123 
49 
104.1 0.000 
IL-12p70 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
42 
85 
113 
135 
50 
105.4 0.000 
IL-13 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
40 
96 
132 
124 
44 
112.9 0.000 
IL-15 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
41 
88 
114 
134 
48 
110.3 0.000 
IL-17 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
40 
87 
117 
129 
53 
98.3 0.000 
IL-1Ra 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
48 
84 
112 
129 
47 
88.5 0.000 
IL-1α 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
43 
86 
133 
125 
47 
102.8 0.000 
IL-1β 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
52 
84 
104 
126 
48 
72.8 0.000 
IL-2 V2.1 40 107.7 0.000 
   
 
124 
V2.2 
V2.3 
V2.4 
V2.5 
88 
122 
130 
49 
IL-3 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
59 
65 
70 
123 
68 
45.3 0.000 
IL-4 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
39 
90 
119 
131 
50 
110.2 0.000 
IL-5 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
41 
92 
96 
135 
51 
100.9 0.000 
IL-6 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
48 
92 
118 
129 
39 
103.1 0.000 
IL-7 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
42 
96 
132 
114 
51 
90.3 0.000 
IL-8 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
55 
85 
89 
121 
52 
54.5 0.000 
IP-10 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
63 
68 
102 
119 
53 
47.8 0.000 
MCP-1 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
60 
80 
73 
104 
69 
18.9 0.001 
MIP-1α 
V2.1 
V2.2 
V2.3 
V2.4 
53 
94 
107 
119 
72.8 0.000 
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 V2.5 43 
MIP-1β 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
48 
93 
119 
118 
47 
78.8 0.000 
TNFα 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
49 
90 
112 
120 
49 
73.4 0.000 
TNF-β 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
40 
89 
118 
135 
47 
114.8 0.000 
VEGF 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
55 
69 
139 
111 
54 
66.8 0.000 
HMGB-1 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
63 
83 
86 
94 
68 
11.9 0.018 
Vitamin-D 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
64 
71 
76 
98 
75 
11.0 0.027 
sLRP-1 
V2.1 
V2.2 
V2.3 
V2.4 
V2.5 
56 
75 
121 
97 
67 
32.1 0.000 
